Universidade Federal de Pernambuco Centro de Ciências Biológicas Programa de Pós Graduação em Ciências Biológicas

RICARDO DE SOUZA SILVA

REVESTIMENTO DE PARTÍCULAS FERROMAGNÉTICAS COM HEPARINA E HEPARAN SULFATO E SEU USO COMO MATRIZ DE AFINIDADE PARA PURIFICAÇÃO DE PROTEÍNAS PLASMÁTICAS

Universidade Federal de Pernambuco Centro de Ciências Biológicas Programa de Pós Graduação em Ciências Biológicas

RICARDO DE SOUZA SILVA

REVESTIMENTO DE PARTÍCULAS FERROMAGNÉTICAS COM HEPARINA E HEPARAN SULFATO E SEU USO COMO MATRIZ DE AFINIDADE PARA PURIFICAÇÃO DE PROTEÍNAS PLASMÁTICAS

Tese apresentada ao Programa de Pós-Graduação em Ciências Biológicas para obtenção do título de Doutor em Ciências Biológicas pela Universidade Federal de Pernambuco.

Orientador: Prof. Dr. Luiz Bezerra de Carvalho Júnior

Recife

Catalogação na Fonte: Bibliotecário Bruno Márcio Gouveia, CRB-4/1788

Silva, Ricardo de Souza

Revestimento de partículas ferromagnéticas com heparina e heparan sulfato e seu uso como matriz de afinidade para purificação de proteínas plasmáticas / Ricardo de Souza Silva. – Recife: O Autor, 2014.

117 folhas: il.

Orientadora: Luiz Bezerra de Carvalho Júnior

Tese (doutorado) – Universidade Federal de Pernambuco. Centro de Ciências Biológicas. Pós-graduação em Ciências Biológicas, 2010.

Inclui bibliografia e anexos

1. Heparina I. Carvalho Júnior, Luiz Bezerra de (orient.) II. Título.

572.567 CDD (22.ed.) UFPE/CCB-2014-090

RICARDO DE SOUZA SILVA

REVESTIMENTO DE PARTÍCULAS FERROMAGNÉTICAS COM HEPARINA E HEPARAN SULFATO E SEU USO COMO MATRIZ DE AFINIDADE PARA PURIFICAÇÃO DE PROTEÍNAS PLASMÁTICAS

Tese apresentada ao Programa de Pós-Graduação em Ciências Biológicas para obtenção do título de Doutor em Ciências Biológicas (Área de concentração Biotecnologia) pela Universidade Federalde Pernambuco.

Aprovada em 26 de fevereiro de 2014 pela comissão examinadora:

Prof^o Dr^o Luiz Bezerra de Carvalho Júnior Orientador e Presidente da Banca

Dr. Gustavo Alves do Nascimento Examinador

Dr^a. Mariana Paola Cabrera Examinadora

Dr. Mário Ribeiro de Melo Júnior Examinador

Dr. Pabyton Gonçalves Cadena Examinador

Para minha mãe, Maria, pelo amor incondicional que sempre demonstrou por mim.

Para minhas irmãs, Lerde, Lourdes, Lúcia, Raimunda e meu irmão José, pelo imensurável carinho e por sempre acreditarem em mim.

AGRADECIMENTOS

A Deus por seu imenso amor. Sem Ele nada disto aqui teria acontecido!

À minha mãe, Maria José de Souza e ao meu pai José da Silva (*in memorian*), pelo carinho, compreensão e atenção depositada durante todos estes anos.

Ao meu irmão José e minhas irmãs Lerde, Lúcia, Ray e Lu. Junto às minhas sobrinhas Mayara e Maria Eduarda e meu cunhado Flávio (*in memorian*) pelo carinho e cooperação em todos os momentos desta e de outras caminhadas!

Ao meu orientador, Prof^o Luiz Carvalho. Meu reconhecimento e gratidão pela paciência, compreensão, oportunidades, simpatia e orientação. Muitíssimo obrigado!

Ao meu grande amigo Givanildo pela grande contribuição dada durante todo o desenvolver deste trabalho. Que Deus ilumine você e toda sua família. Obrigadão!!!!!

A Aurenice pela ajuda, amizade, respeito e bons momentos compartilhados.

A todos os colegas de laboratório, em especial: Romero, Fábio Fidélis, Mariana Cabrera, Luiza Lima, Amanda, Larissa, Sinara e Lúcia, pela amizade e maravilhosos momentos passados juntos. Valeu pessoal, torço por todos vocês!

A Dyego Assis, Renata Maia, Adeilton Oliveira, Paula Barbosa, Paula Maia, Dutra, Juh, Amanda, Dijaina, John Two, Beth, Jefferson, Isaias, Ayanna e Fernanda, pela amizade!

À CAPES, pelo aporte financeiro, e a todos os que fazem o LIKA pelo tratamento conferido a mim.

A todos e a todas que contribuíram de forma direta ou indiretamente para esta pesquisa.

MUITO OBRIGADO A TODOS VOCÊS!!!



Resumo

Métodos de separação por afinidade têm se revelado eficazes e econômicos. Eles se baseiam na formação de um complexo estabelecido entre duas biomoléculas afins a um suporte insolúvel em água. Lavagens iniciais deste compósito removem impurezas de sorte que em uma segunda etapa o complexo é desfeito, liberando a biomolécula de interesse mediante seu rompimento (força iônica, pH, etc.). Dentre os diferentes métodos, aqueles baseados em suportes magnéticos têm as vantagens de fácil síntese, manuseio e o derivado ser recuperado por meio de um campo magnético. Esta tese se postulou a revestir partícula magnéticas com heparina (HEP) e heparan sulfato (HS) uma vez que esses glicosaminoglicanos são muito negativamente carregados e formam complexos com proteínas, por exemplo, proteínas plasmáticas. Três tipos de materiais foram sintetizados: polietilenotereftalato magnetizado (mPET), magnetita (MAG) e magnetita revestida com polianilina (mPANI). Inicialmente, filmes de PET sofreram hidrazinólise e o pó PET-hidrazida obtido foi magnetizado pelo método de co-precipitação em solução de cloretos férrico e ferroso. A MAG foi sintetizada conforme descrito acima, porém, sem adição do PET, e posteriormente foi revestida com PANI (mPANI). HEP e HS foram ativados com carbodiimida e N-hidroxissuccinimida e incubados com os suportes para que ocorressem o revestimento das partículas, produzindo os seguintes derivados magnéticos: mPET-HEP; mPANI-HEP; MAG-HEP; mPET-HS e mPANI-HS. As amostras de mPET-HEP foram investigadas por análise elementar e espectroscopia de infravermelho. A composição centesimal delas mostrou um aumento na razão carbono: nitrogênio, presumindo ser devido à imobilização de heparina. O espectro de infravermelho do derivado contendo heparina apresentou bandas em 1653 cm-1 e 1547 cm-1, característicos da ligação amida, formada pela conjugação. O derivado mPANI imobilizou cerca de 37% da heparina ofertada, embora a magnetita pura (MAG) também tenha imobilizado, porém em menor grau. Todas estas matrizes demonstraram uma boa estabilidade em 10 ciclos consecutivos de reutilização mesmo após 2 anos estocadas a 4°C. Quanto ao HS, este foi covalentemente fixado às partículas mPANI e mPET em torno de 35 µg e 38,6 µg por mg de suporte respectivamente, no entanto também foi adsorvido (18µg/mg) sobre as partículas controle de MAG. Indícios do sucesso da imobilização nestes compósitos foram a demonstração de que a heparina fixava o corante azul de metileno e retardava o tempo de coagulação do plasma recalcificado quando em contato com estes suportes. Finalmente, todos os derivados magnéticos foram incubados com plasma humano e lavados posteriormente com gradientes de NaCl para liberar as proteínas fixadas e detectá-las a 280nm. Eletroforese destas proteínas revelaram bandas referentes à antitrombina (58kDa) e as suas dosagens nos plasmas e eluatos confirmaram a eficiência do método de separação. Nos derivados mPET-HS e mPANI-HS, além da antitrombina, importantes fatores da coagulação também foram observados na eletroforese e comprovada a sua separação através de testes de coagulação específicos. Portanto, os resultados mostraram que estes compósitos produzidos são promissores na purificação da antitrombina e outros fatores da coagulação presentes no plasma humano.

Palavras-chaves: heparina; heparan sulfato; imobilização; polianilina; polietilenotereftalato; separação.

Abstract

Affinity separation methods have shown to be effective and economical. They are based on the formation of complex established between two related biomolecules to a water insoluble support. Initial washes of these composites remove impurities so that in a second step the complex is broken, releasing the biomolecule of interest through its breakup (ionic strength, pH, etc.). Among the different methods, those based on magnetic support have the advantages of easy synthesis, handling and the derivative to be retrieved by means of a magnetic field. This thesis has been postulated to coat magnetic particle with heparin (HEP) and heparan sulfate (HS) since these are very negatively charged glycosaminoglycans and form complexes with proteins, for example, plasma proteins. Three types of materials were synthesized: magnetized polyethylene terephthalate (mPET), magnetite (MAG) and magnetite coated with polyaniline (mPANI). Initially, PET films suffered hydrazinolysis and PET-hydrazide powder obtained was magnetized by co-precipitation method in a solution of ferric and ferrous chlorides. Initially, PET films suffered hydrazinolysis and PET-hydrazide powder obtained was magnetized by co-precipitation method in a solution of ferric and ferrous chlorides. The MAG was synthesized as described above but without the addition of PET and was subsequently coated with PANI. Heparin and heparan sulfate were activated with carbodiimide and N-hydroxysuccinimide and incubated with the supports for coating occurs and generate the following magnetic derivatives: mPET-HEP; mPANI-HEP; MAG-HEP; mPET-HS e mPANI-HS. The samples mPET-HEP were investigated by elemental analysis and infrared spectroscopy. The centesimal composition of them showed an increase in carbon : nitrogen ratio, presumed to be due to immobilization of heparin. The infrared spectrum of the heparin derivative showed bands at 1653 cm-1 and 1547 cm-1 which are characteristic of the amide linkage formed by conjugation. The mPANI derivative immobilized about 37% of heparin offered, although the pure magnetite (MAG) also has immobilized, but to a lesser degree. All these matrices showed good stability in 10 consecutive cycles of reuse even after 2 years stored at 4°C. As regards the heparan sulfate, it was covalently immobilized to particles mPANI and mPET about 35 µg and 38.6 µg respectively per mg of support, however it was also adsorbed (18µg/mg) on control particles (MAG). Evidence of the success of immobilization in these composites were the demonstration that heparin fixed the methylene blue dye and retarded the clotting time of plasma recalcified when in contact with these supports, Finally, all magnetic derivatives were incubated with human plasma and subsequently washed with NaCl gradients to release fixed proteins and detect them at 280 nm. Electrophoresis of these proteins revealed bands related to antithrombin (58kDa) and their dosages in plasma and eluates confirmed the efficiency of the separation method. In derivatives mPET-HS and mPANI-HS, beyond antithrombin, important coagulation factors were also observed in electrophoresis and confirmed their separation through specific coagulation tests. Therefore, the results showed that these composites produced are promising and important to separate antithrombin and others coagulation factors present in human plasma.

Keywords: heparin, heparan sulfate; immobilization; polyaniline, polyethylene terephthalate; separation.

LISTA DE FIGURAS

Capítulo 1

Figura 1. Métodos de imobilização de biomoléculas (adaptado a partir de Bickerstaff, 1997)	18
Figura 2. Esquema representativo da reação de ativação dos grupamentos carboxílicos através do tratamento com a carbodiimida (EDAC) e o N-hidroxi-succinamida (Sulfo-NHS).	20
Figura 3 . Síntese de Polietilenotereftalato a partir da reação de esterificação entre o ácido tereftálico e o etilenoglicol	22
Figura 4. Aplicações do PET na tecelagem (A), embalagem (B), e prótese no tronco venoso braquiocefálico esquerdo (C). Fontes: (A) – www.asdivers.com.br; (B) – www.in.com.br; (C) – www.jornaldepneumologia.com.br. Sites acessados no dia 08/10/13	23
Figura 5 . Conversão das folhas de Dacron em pó e sua posterior magnetização. (A) Dacron em forma de fitas; (B) Fitas de Dacron cortadas pedaços; (C) Pó de Dacron após o processo de hidrazinólise de coloração branco-amarelada (esquerda) e seu derivado magnetizado (direita) de coloração negra; (D) Recuperação do Dacron com o auxílio de campo magnético	24
Figura 6. Funcionalização do Dacron com grupos hidrazida	25
Figura 7. Diferentes estados de oxidação da polianilina. Fonte: CHI, et al., 2009	26
Figura 8. Repetição das unidades dissacarídicas na heparina ($X = H$ ou SO_3^- , $Y = Ac$, SO_3^- , ou H)	27
Figura 9. A – Estrutura da antitrombina; B – Antitrombina complexada com uma sequência pentassacarídica de heparina; C – Sequência pentassacarídica da heparina essencial para ocorrer a interação heparina-AT. Fonte: http://en.academic.ru/pictures/enwiki/65/Antithrom%2Bheparin.jpeg	30
Figura 10. Princípios da adsorção por afinidade	31
Capítulo 2	
Figura 1. Infrared spectra of derivatives. In ascending order: magnetite; PET-hydrazide; mPET and mPET-HEP	51
Figura 2. Electrophoresis of protein fractions of plasma obtained with the use of magnetic particles. Elutions were carried out using increasing NaCl concentrations (0.25; 0.5 and 1.0 M) in the magnetic derivatives: a) mPET-HEP and b) mPET (control).AT: Standard Antithrombin. *Elutionsperformedin supportsstoredfor 24	

months	52
Figura 3. Activity of antithrombin present in fresh plasma and after direct contact with the support: a) Immediately synthesized (time zero) and b) 24 months stored at 4°C	53
Figura 4. Activated partial thromboplastin time (aPTT) of fresh plasma performed by adding small aliquot of the eluate (1.0 M) of magnetic derivatives: a) Immediately synthesized (time zero) and b) 2 years stored at 4°C	
Capítulo 3	
Figura 1. Magnetic matrix: (a) pure magnetite, (b) magnetite coated with PANI	64
Figura 2. Affinity chromatography of human plasma protein using magnetic particle washed with phosphate buffer (PB) and increasing NaCl concentrations (0.25; 0.5; 1.0 and 2.0 M)	66
Figura 3 . <i>Electrophoresis</i> . The figures indicate the number of the fractions, according to the Fig. 2, collected by increasing NaCl concentrations (0,25; 0.5 and 1.0 M) from the plasma protein adsorbed onto the: a) mPANI-HEP; b) MAG-HEP and c) MAG. The rectangle shows the fractions that presented higher aPTT antithrombotic activity values. AT: Standard Antithrombin. * Elutions performed in supports stored for 2 years	67
Figura 4. Activity of antithrombin present in fresh plasma and after direct contact with the support: a) Immediately synthesized (time zero) and b) 24 months stored at 4°C	69
Figura 5. Activated partial thromboplastin time (aPTT) of fresh plasma performed by adding small aliquot of the eluate (1.0 M) of derivatives magnetic: a) Immediately synthesized (time zero) and b) 2 years stored at 4°C	69
Capítulo 4	
Figura 1 . Affinity chromatography of human plasma proteins using magnetite coated with polyaniline and heparan immobilized: mPANI-HS was incubated with human plasma and washed with phosphate buffer pH 7.2, to balance the absorbance (280 nm) – 20 th fraction: the particles were then washed with buffer containing increasing concentrations of NaCl (0.5M; 1.0M; 1.5M and 2.0M).	82
Figura 2 . Affinity chromatography of human plasma proteins using ferromagnetic PET with heparan sulfate immobilized: mPET-HS was incubated with human plasma and washed with phosphate buffer pH 7.2, to balance the absorbance (280 nm) –20 th fraction: the particles were then washed with buffer containing increasing concentrations of NaCl (0.5M; 1.0M; 1.5M and 2.0M)	83

Figura 3. SDS-PAGE of the Fractions collected from the plasma protein adsorbed onto: A) mPANI-HS and B) mPET-HS. Elutions were carried out using phosphate buffer (PB) and increasing NaCl concentrations (0.5; 1.0; 1.5 and 2.0 M). The figures indicate the number of the fractions (f) collected according to the Fig.1 and Fig.2. Bands: a) factor XI; b) protein S; c) factor II; d) AT: antithrombin; e) factor VII; f) factor III and g) factor IIa.....

85

LISTA DE TABELAS

Capítulo 1

Tabela 1. Considerações fundamentais na seleção do suporte para imobilização (BICKERSTAFF, 1997)			
Tabela 2. Principais derivados bioativos desenvolvidos na UFPE com suas respectivas biomoléculas imobilizadas	22		
Tabela 3. Diferenças estruturais entre a heparina e o heparan sulfato; (SAMPAIO et al, 2006)	28		
Tabela 4. Exemplos de proteínas de ligação aos glicosaminoglicanos (GAGs) e a sua atividade biológica. <i>Fonte: adaptado de Esko e Linhardt</i> , 2009.	29		
Capítulo 2			
Tabela 1. Methylene blue (MB) adsorption on derivatives.	50		
Tabela 2. Elemental composition of derivatives.	51		
Tabela 3. Anticoagulant/antithrombotic activity of magnetic particles	53		
Capítulo 3			
Tabela 1. Recovery of heparin (3mg) not fixed on magnetic particles	65		
Tabela 2. Activity anticoagulant / antithrombotic directlyon magnetic particles	68		
Capítulo 4			
Tabela 1 . Recovery heparan sulfate (3mg) not fixed to magnetic support mPANI and mPET	81		
Tabela 2 . The activated partial thromboplastin time (aPTT), prothrombin time (PT) and antithrombin activity of the fractions collected from the elution of the plasma proteins adsorbed onto the: a) mPANI-HS and b) mPET-HS	84		

LISTA DE ABREVIATURAS E SIGLAS

Abs absorbância

APS persulfato de amônio

AT antitrombina

bFGF fator de crescimento de fibroblastos básico **EDAC** 1-etil-3-(3-dimetilaminopropil) carbodiimida

Fe⁺² fon ferroso Fe⁺³ fon férrico FN fibronectina

GAG glicosaminoglicano
GlcA ácido glucurônico
GlcN glucosamina
HCl ácido clorídrico
IdoA ácido idurônico

MAG Partículas de magnetita pura

HEP HeparinaHS Heparan sulfatoPET Polietilenotereftalato

PANI Polianilina

mPET Polietilenotereftalato magnetizado

mPET-HEP Polietilenotereftalato magnetizado e heparina imobilizada

mPET-HS Polietilenotereftalato magnetizado e heparan sulfato imobilizado

mPANI Partículas de magnetita revestidas com polianilina

mPANI-HEP Magnetita revestida com polianilina e heparina imobilizada

mPANI-HS Magnetita revestidas com polianilina e heparan sulfato imobilizado

MAG-HEP Magnetita com heparina imobilizada

SDS Dodecil sulfato de sódio PAGE Gel de Poliacrilamida

nm Nanômetroμm Micrômetro°C Grau celsius

pH Potencial hidrogeniônico

Tris Tris (hidroximetil) aminometano

IV Infravermelho

FTIR Fourier Transform Infrared λ Comprimento de onda

Oe Oersted

cm⁻¹ número de ondas

mg miligrama grama g min minuto segundo S h hora M molar mM milimolar mLmililitro microlitro μL μmol micromol

SUMÁRIO

1 Introdução	15
Capítulo 1	
2 Revisão da Literatura	17
2.1 Imobilização de Biomoléculas	17
2.2 Suporte Magnético	21
2.2.1 Dacron	23
2.2.2 Polianilina	25
2.3 Heparina	26
2.3 Heparan Sulfato	28
2.4 Proteínas de ligação aos Glicosaminoglicanos (GAGs)	28
2.5 Adsorção por afinidade à heparina e ao heparan Sulfato (HS)	31
3 Referências	33
4 Objetivos	43
4.1 Objetivos Gerais	43
4.2 Objetivos Específicos	43
Capítulo 2	
5 Artigo a ser submetido ao Periódico <i>Biomaterials</i>	73
Capítulo 3	
6 Artigo a ser submetido ao Periódico Reactive and Functional Polymers	59
Capítulo 4	
7 Artigo a ser submetido ao Periódico Composites Science and Technology	73
8 Conclusões	90
9 Anexos	92
9.1 Instruções para autores	92
9.2 Trabalhos apresentados em Congressos	116
9.3 Premiações	116
9.4 Orientações e Colaborações	117

1 Introdução

Imobilização de biomoléculas consiste em um método pelo qual elas são quimicamente ou fisicamente aprisionadas em um suporte insolúvel ou solúvel em água. A insolubilidade em água, conferida a estas biomoléculas após a imobilização, torna este material facilmente removível do meio de incubação, possibilitando a obtenção de produtos isentos de contaminação e com uma maior estabilidade mecânica. Além disso, a biomolécula imobilizada pode reter parte ou a totalidade de suas propriedades biológicas (TWEEDDALE e REDMOND, 1998; KORECKÁ et al., 2005).

A heparina e o heparan sulfato (HS) são polissacarídeos lineares sulfatados pertencentes à família dos glicosaminoglicanos (GAGs). A heparina tem seu uso bastante difundido na clínica devido à sua propriedade anticoagulante (VISKOV et al., 2013). Além disso, é bastante conhecida por apresentar afinidade com várias proteínas, as chamadas "proteínas de ligação à heparina", tais como o fator de crescimento de fibroblastos básico (bFGF), fator de crescimento endotelial vascular (VEGF), a fibronectina (FN) e antitrombina (AT), além de desempenhar um importante papel na regulação da atividade e estabilidade destas proteínas (RODGERS et al., 2009; OLSON et al., 2010; ARISAKA et al, 2013). Outras proteínas biologicamente ativas interagem com a heparina, tais como, alguns fatores da coagulação sanguínea, lipases, etc. (KARLSSON e WINGE, 2004). Essas interações desempenham papéis importantes nos processos fisiológicos, bem como nos processos patológicos (OLAD e NABAVI, 2007). O heparan sulfato, por seu turno, devido à sua grande diversidade estrutural, também é capaz de vincular e interagir com uma grande variedade de proteínas: fatores de crescimento, quimiocinas, componentes da matriz extracelular, DNA e RNA polimerases, dentre outras. (FURUKAWA e BHAVANANDAN 1983; AVIEZER e YAYON 1994; KOOPMANN et al. 1999; SASISEKHARAN et al. 2002).

A mudança do microambiente ao redor das biomoléculas imobilizadas pode ocasionar mudanças nas suas propriedades, quando as mesmas são comparadas à sua forma nativa (ARAÚJO et al., 1997; GILL & BALLESTEROS, 2000). Assim, novas metodologias são constantemente propostas para a imobilização destes componentes biológicos, uma vez que nenhuma matriz é universal ou perfeita, ou seja, não há suporte que preserve totalmente a atividade da biomolécula (WEETALL & LEE, 1989; HERMANSON et al., 1992; BARBOSA et al., 2000; BUCUR et al., 2004).

A separação de biomoléculas de seus contaminantes ainda não é uma tarefa trivial. Existem vários métodos de purificação e aqueles baseados na afinidade entre uma

biomolécula e seu ligante são os mais específicos. A adsorção por afinidade é uma ferramenta bastante útil na purificação de proteínas. Contudo, métodos preparatórios são normalmente utilizados para eliminar materiais particulados que podem obstruir as colunas clássicas de leito empacotado. Dessa forma, técnicas alternativas de separação por afinidade têm sido sugeridas para contornar esse problema e dentre essas se encontram as separações utilizando partículas magnéticas. Sendo a heparina um ligante já bem conhecido das cromatografias de afinidade, e a versatilidade de interações entre o heparan sulfato com diversas proteínas, o presente trabalho descreveu a síntese e caracterização de partículas ferromagnéticas e a imobilização destes dois glicosaminoglicanos no Dacron ferromagnético e em magnetita revestida com Polianilina (PANI) além de estudar o comportamento destes derivados para separação/purificação de proteínas usando o método de afinidade.

2 Revisão da Literatura

2.1 Imobilização de Biomoléculas

Imobilização é o método pelo qual moléculas (por exemplo, fármacos, carboidratos, ácidos nucléicos e proteínas) são quimicamente ou fisicamente aprisionadas em um suporte insolúvel ou solúvel em água. Dessa forma, a utilização da biomolécula torna-se economicamente viável e de grande interesse industrial. Além disso, a fixação a matrizes inorgânicas combina a alta seletividade das reações com as particularidades químicas e físicas do suporte (KONG e FUN HU, 2012).

Três aspectos da imobilização devem ser observados: método de imobilização (tendo em vista o objetivo da imobilização), natureza do suporte (apresentação do suporte tendo em vista suas características físico-químicas e mecânicas) e molécula a ser imobilizada (grupamentos funcionais disponíveis).

BICKERSTAFF (1997) cita os principais modos de interação entre as biomoléculas a serem imobilizadas com a respectiva matriz: formação de redes interpenetradas (enclausuramento), adsorção física, ligação cruzada, encapsulamento e ligação covalente (Figura 1) e considerações acerca do suporte e métodos de imobilização (Tabela 1). Dentre as técnicas de imobilização conhecidas pode-se citar: adsorção, onde há uma interação física não-específica entre a biomolécula e a superfície do suporte; oclusão ou aprisionamento em um suporte semipermeável ou no interior de polímeros; reações cruzadas ou cross-linking que consiste na ligação das próprias biomoléculas entre si formando uma malha que também pode ser insolúvel; e ligação covalente. Esta última apresenta como principais vantagens uma baixa lixiviação da biomolécula imobilizada e elevada estabilidade do derivado obtido. Diante disto, é muito importante escolher um método de imobilização que conserve grande parte das características da biomolécula imobilizada, pois uma simples alteração no microambiente destas biomoléculas imobilizadas pode levar a mudanças em suas propriedades (GUISAN, 2006; TWEEDDALE & REDMOND, 1998; KORECKÁ et al., 2005).




Figura 1. Métodos de imobilização de biomoléculas (adaptado a partir de Bickerstaff, 1997).

Tabela 1. Considerações fundamentais na seleção do suporte para imobilização (BICKERSTAFF, 1997).

Propriedades	Pontos para consideração		
	Resistência, não compressão das partículas, área de superfície		
Física	disponível, forma (partículas esféricas/lâminas/fibras), grau de		
FISICa	porosidade, volume do poro, permeabilidade, densidade e		
	vazão.		
	Hidrofilicidade (adsorção de água pelo suporte), neutralidade		
Química	em relação à biomolécula, disponibilidade de grupos funcionais		
	para modificação e regeneração/reutilização do suporte.		
	Estocagem, atividade residual da enzima, regeneração da		
Estabilidade	atividade enzimática (reutilização), estabilidade mecânica do		
	material do suporte.		
D	Ataque microbiano, rompimento por agentes químicos, pH,		
Resistência	temperatura e solventes orgânicos.		
	Biocompatibilidade, toxicidade dos componentes e reagentes,		
C	saúde e segurança dos operadores do processo e dos usuários		
Segurança	do produto, especificações da preparação imobilizada para		
	aplicações em alimentos, farmacêuticas e médicas.		
	Disponibilidade e custos do suporte, reagentes químicos e		
	equipamentos, habilidade técnica requerida, impacto ambiental,		
Economia	preparação em escala industrial, possibilidade para aumentar a		
	produção, processamento contínuo, reutilização do suporte,		
	nível de risco calculado ou contaminação zero.		
Reação	Vazão, carregamento do suporte com a enzima e produtividade		
	catalítica, cinética da reação, reações laterais, sistema de		
	múltiplas enzimas, tipo de reator, limitações de difusão e		
	transferência de massa de cofatores, substratos e produtos.		

Entre os vários processos citados na tabela 1 para imobilização de biomoléculas, o emprego da imobilização por ligação covalente é o que está associado a uma maior estabilidade. Nesse método ocorre uma reação química entre grupos funcionais da molécula e grupos reativos presentes no suporte.

A heparina e o heparan sulfato apresentam grupos funcionais (sulfatos e carboxilatos) reativos, o que proporciona a sua fácil imobilização a uma matriz, por isso o seu uso tem sido alvo de pesquisas na área de imobilização de biomoléculas (MURUGESAN et al., 2008).

Para que ocorra a ligação covalente da heparina e do heparan sulfato, primeiramente é necessário que seus grupos carboxílicos passem por um processo de ativação através da adição de EDAC (*1-etil-3-(3-dimetilaminopropilcarbodiimida*), Figura 2. O EDAC ativa a heparina levando à formação do *o*-acilureia, um composto intermediário, que apresenta um grupamento éster bastante reativo e fácil de sofrer hidrólise. Para resolver esse problema é adicionado o NHS (N-hidroxi-succinamida) que vai reagir com o grupo éster do composto intermediário deixando-o mais estável. Logo, em presença de um grupamento amino do suporte, este irá reagir com a carbonila do éster formando uma ligação amida (OLIVEIRA et al., 2003).




Figura 2. Esquema representativo da reação de ativação dos grupamentos carboxílicos através do tratamento com a carbodiimida (EDAC) e o N-hidroxi-succinamida (Sulfo-NHS); (adaptada do livro: Bioconjugate Techniques; 2ª Edição).

Quando imobilizada, a heparina pode interagir com fatores da coagulação, funcionando como um ligante de afinidade capaz de interagir com proteínas. Além disso, permitir a troca de cátions de alta capacidade devido à presença de grupos sulfatos aniônicos em sua estrutura (KRAPFENBAUER e FOUNTOULAKIS, 2009). Nesse contexto, o uso de heparina imobilizada a um suporte tem sido ferramenta para a produção de dispositivos biomédicos. Tais materiais são geralmente usados em cirurgias cardíacas para alcançar efeitos antitrombogênicos, baixo grau de ativação do complemento e redução da adesão bacteriana

(YE et al, 2013). Superfícies heparinizadas também mostram redução da adesão plaquetária, aumento do tempo de recalcificação do plasma e do tempo de tromboplastina parcialmente ativada (MURUGESAN et al, 2008).

2.2 Suporte Magnético

Um suporte ou matriz é qualquer material ao qual um ligante bioespecífico pode ser ligado. Escolher a melhor matriz para uma determinada aplicação, ocasionará um uso mais eficiente e otimizado da mesma. Ao escolher um suporte, duas premissas devem ser devidamente observadas: as suas propriedades físico-químicas e a possibilidade de regeneração do material (MACIEL, 2012). Os suportes utilizados na imobilização de biomoléculas tendem a possuir um bom perfil como resistência física, insolubilidade, resistência a ataques microbianos, além de estabilidade mecânica e térmica (CARAMORI e FERNANDES, 2004). E, quando magnetizados, a recuperação do compósito suporte-biomolécula pode facilmente ser obtida mediante a aplicação de um campo magnético.

As partículas magnéticas foram empregadas pela primeira vez na década de 1940 como uma nova tecnologia no tratamento de água poluída (ARIAS et al., 2001). Nos dias atuais, a síntese e aplicação das partículas magnéticas funcionalizadas vêm despertando grande interesse em diversas áreas (WU et al., 2008; HAO et al., 2010). No entanto, deve haver um cuidado ao escolher o suporte para determinada biomolécula, pois o suporte usado na imobilização pode afetar, significantemente, as características do material imobilizado (SRIVASTAVA et al., 2001), bem como a carga na superfície do carreador (GODJEVARGOVA et al., 2003). A imobilização na face externa do suporte é um dos mais eficientes meios de diminuir a resistência de deslocamento de massa. Um braço espaçador entre o suporte e a biomolécula pode diminuir as mudanças na estrutura desta, e torná-la mais flexível, levando, portanto, a um maior potencial de estabilidade de suas atividades (SRIVASTAVA et al., 2001).

Sendo as técnicas de imobilização de enzimas e carboidratos em diferentes suportes magnéticos uma das principais linhas de pesquisa desenvolvida no setor de Bioquímica do Laboratório de Imunopatologia Keizo Asami (LIKA), a tabela 2 apresenta alguns dos derivados bioativos, matrizes e respectivas biomoléculas imobilizadas desenvolvidos na UFPE nos últimos dez anos pelo grupo de pesquisa do LIKA.

Tabela 2. Principais derivados bioativos desenvolvidos na UFPE com suas respectivas biomoléculas imobilizadas.

Suporte	Biomolécula Imobilizada	Referência Bibliográfica
Dacron	Antígeno (SWAP) de Schistosoma	Montenegro et al., 1999
	mansoni	
Papel de filtro	Albumina de Soro Humano	PINHEIRO et al., 1999
Plastificado com	Antígeno de Yerssinia pestis	BARBOSA et al., 2000
PVA*-	β -galactosidase	NERI et al., 2009
glutaraldeído		
Compósitos de	Antígeno de Toxocara canis	COELHO et al., 2001
polianilina e		
Dacron	Tripsina	MARCIEL et al., 2012
Compósito de	Antígenos de Trypanossoma cruzi e	BARROS et al., 2002
polisiloxano e	Schistosoma mansoni	COÊLHO et al., 2003
álcool polivinílico		COELHO et al., 2002
Argila Magnética	Invertase	CABRERA et al., 2013
Diatomito	Invertase	CABRERA et al., 2013
Magnético		

* - PVA – álcool polivinílico

Dentre vários procedimentos sintéticos desenvolvidos para se obter partículas magnéticas, o procedimento mais barato, simples e até ecologicamente correto é o método de coprecipitação, o qual envolve a precipitação simultânea de íons Fe⁺³ e Fe⁺² em meio básico e aquoso (KANG et al., 1996; QU et al., 1999).

Os materiais magnéticos modificados são constituídos por um núcleo de óxido de ferro revestido com um polímero. Esse revestimento possui grupos ativos que podem ser conjugados a biomoléculas tais como carboidratos, proteínas e enzimas (MA et. al, 2003; YAMAURA et al., 2004). As partículas de magnetita superparamagnéticas revestidas com

polímeros são usualmente formadas por núcleos magnéticos responsáveis por uma resposta magnética forte e uma camada polimérica para fornecer grupos funcionalizáveis e característicos (WUNDERBALDINGER et al., 2002).

2.2.1 Dacron

Dacron, marca registrada para uma fibra de poliéster, é um polímero formado pela condensação do etilenoglicol (um diálcool) com o ácido tereftálico (ácido dicarboxílico). Esta condensação (esterificação) forma um longo poliéster chamado polietilenotereftalato ou PET (Figura 3). Utiliza-se principalmente na forma de fibras para tecelagem e de embalagens para bebidas, além de próteses e suturas (Figura 4). Pode ser encontrado nos mais diversos formatos, mais freqüentemente em pellet e folhas.

Figura 3. Síntese de Polietilenotereftalato a partir da reação de esterificação entre o ácido tereftálico e o etilenoglicol.



Figura 4. Aplicações do PET na tecelagem (A), embalagem (B), e prótese no tronco venoso braquiocefálico esquerdo (C). Fontes: (A) – www.asdivers.com.br; (B) – www.in.com.br; (C) – www.jornaldepneumologia.com.br. Sites acessados no dia 08/10/13.

Este poliéster também vem sendo empregado como matriz na imobilização de biomoléculas, pois possui um bom perfil como resistência física, insolubilidade, resistência a ataques microbianos além de estabilidade mecânica e térmica (CARAMORI & FERNANDES, 2004).

Para que ocorra a imobilização a este suporte é necessário que ele seja funcionalizado, ou seja, apresente grupos funcionais disponíveis para a imobilização. A primeira funcionalização do Dacron foi demonstrada por Weetall (1970) que propôs quatro reações para introduzir grupos aril-azidas para imobilização de L-asparaginase. A reação de Passerini também já foi empregada para imobilizar enzimas ao Dacron (GOLDSTEIN et al., 1977). A reação de Passerini foi descrita em 1921 e é uma reação multicomponente clássica entre ácidos carboxílicos, aldeídos ou cetonas e isocianetos, conduzindo a interessantes compostos peptidomiméticos.

Melo (1984) descreveu uma metodologia para converter folhas de Dacron em um pó, num processo chamado hidrazinólise, onde o polímero é clivado e sofre uma redução em seu peso molecular sendo convertido em pó. E no intuito de facilitar a recuperação do suporte, Carneiro-Leão et al., (1991) propuseram a magnetização destas partículas, o que tornou este processo fácil e rápido com o auxílio de um campo magnético. (Figura 5 e 6).




Figura 5. Conversão das folhas de Dacron em pó e sua posterior magnetização. (A) Dacron em forma de fitas; (B) Fitas de Dacron cortadas pedaços; (C) Pó de Dacron após o processo de hidrazinólise de coloração branco-amarelada (esquerda) e seu derivado magnetizado (direita) de coloração negra; (D) Recuperação do Dacron com o auxílio de campo magnético.

O pó obtido é mecanicamente resistente e não biodegradável. Essas propriedades o qualificam como um suporte adequado para imobilização. E quando magnetizado possibilita sua rápida separação de uma mistura reacional.

Figura 6. Funcionalização do Dacron com grupos hidrazida.

2.2.2 Polianilina

Polianilina (PANI) é um polímero condutor da família dos polímeros flexíveis. Apesar de ter sido descoberta há mais de 150 anos, só recentemente a polianilina recebeu a atenção da comunidade científica devido à descoberta de sua alta condutividade elétrica. Entre a família de polímeros condutores, polianilina é única devido à sua facilidade de síntese e estabilidade ambiental. Embora os métodos de síntese para produzir polianilina sejam bastante simples, o seu mecanismo de polimerização e a natureza exata de sua química de oxidação são bastante complexas. Devido à sua química rica, a polianilina tem sido um dos polímeros mais estudados nos últimos 20 anos. Dentre esses estudos, temos seu uso no revestimento de compósitos: imobilização de horseradish peroxidase (HRP) em magnetita revestida com PANI e ativada com glutaraldeído (BARBOSA et al, 2012); tripsina imobilizada em polivinilalcool revestido também com PANI e tratado com gluteraldeído (CARAMORI et al, 2011).

A PANI é um polímero que apresenta maior estabilidade química na sua forma condutora, facilidade de polimerização e baixo custo do monômero (COELHO et al., 2001). O revestimento de uma matriz magnética com polianilina, por exemplo, devido a sua fácil síntese (eletroquimicamente ou mediante uso de agentes oxidantes), torna-a atrativa para aplicação como matriz de imobilização de moléculas (FERNANDES et al., 2003; NGAMNA et al., 2005; SINGH et al., 2006). A PANI pode ocorrer em diferentes estados de oxidação (Figura 7), dos quais a forma sal de esmeraldina, 50% oxidada, é a mais estável (MACIEL, 2012).

Figura 7. Diferentes estados de oxidação da polianilina. Fonte: CHI, et al., 2009.

2.3 Heparina

A heparina é um polissacarídeo com propriedades biológicas e químicas singulares, amplamente conhecido como uma droga anticoagulante. Ela foi descoberta em 1916 por Jay McLean, um estudante de medicina da Johns Hopkins University. Contudo, maiores detalhes sobre sua estrutura só foram desvendados em 1968. Assim, finalmente a heparina foi denominada como um polissacarídeo linear sulfatado, formado por unidades dissacarídicas contendo ácido idurônico e glicosamina. (NADER et al., 2001; CAPILA e LINHARDT, 2002; PETITOU et al., 2003).

Atualmente sabe-se que a heparina é um polímero linear, consistindo de unidades repetitivas de resíduos de ácido piranosilurônico e 2-amino-2-desoxiglicopiranose

(glicosamina) ligados por ligações 1→4 (Figura 8). Os resíduos de ácido urônico consistem tipicamente de 90% de ácido L-idurônico e 10% de ácido D-glicurônico. A heparina possui a maior densidade de carga negativa que qualquer macromolécula biológica e isto é um resultado do alto conteúdo de grupos sulfonatos e carboxilatos. A estrutura mais comum que ocorre na heparina é o dissacarídeo trissulfatado. Entretanto, há uma variação estrutural deste dissacarídeo, o que leva a uma microheterogeneidade da heparina. O grupo amino do resíduo de glicosamina pode ser substituído com grupos acetil ou sulfonato ou não substituído. As posições 3 e 6 dos resíduos de glicosamina podem ser substituídas com um grupo O-sulfonato ou não substituídas. O ácido urônico pode conter também um grupo 2-O-sulfonato. Além disso, o glicosaminoglicano heparina tem uma faixa de peso molecular de 5-40 kDa, com um peso molecular médio de aproximadamente 15 kDa e uma carga negativa média de aproximadamente −75 (NADER et al., 2001; CAPILA & LINHARDT, 2002; PETITOU et al., 2003).

Figura 8. Repetição das unidades dissacarídicas na heparina (X = H ou SO₃, Y = Ac, SO₃, ou H).

A heparina é conhecida como sendo o anticoagulante mais comumente utilizado na clínica (MENG et al., 2009). Ao longo das últimas décadas, foi mostrado que a heparina está envolvida em muitos processos biológicos através da sua interação com um elevado número de proteínas (LEVER e PAGE, 2012). E que devido a sua estrutura altamente carregada, também está envolvida na regulação de eventos importantes como a sinalização celular e o controle de uma variedade de funções biológicas (HANSEN et al., 2013).

2.3 Heparan Sulfato

O heparan sulfato possui uma estrutura química semelhante à da heparina (Tabela 3). O heparan sulfato também tem seu grupo N-Glicosamina, N-acetilado ou N-sulfatado. Entretanto, na heparina, o grupo N-acetil corresponde a menos que 5%. Desta forma, a heparina demonstra possuir um maior grau de sulfatação (2,3 - 2,8 sulfato/dissacarídeo) quando comparado ao heparan sulfato (0,6 - 1,5 sulfato/dissacarídeo).

Diversos trabalhos na literatura demonstram claramente um alto número proteínas biologicamente ativas que podem interagir com o heparan sulfato. O heparan, devido à sua grande diversidade estrutural é capaz de vincular e interagir com uma grande variedade de proteínas: fatores de crescimento, quimiocinas, componentes da matriz extracelular, DNA e RNA polimerases, fatores da coagulação dentre outras. (AVIEZER e YAYON 1994; KOOPMANN et al., 1999; SASISEKHARAN et al., 2002).

Tabela 3. Diferenças estruturais entre a heparina e o heparan sulfato; (SAMPAIO et al, 2006).

G.L.G.	Dissacarídeos		
GAG	Ácido Urônico	Ligação	Glicosamina
	D-GlcA	$\beta 1 \rightarrow 4$	D-GlcN-Ac
	D-GlcA	$\beta 1 \rightarrow 4$	D-GlcN-Ac (6S)
Heparan	D-GlcA	$\beta 1 \rightarrow 4$	D-GlcN (S)
Sulfato	D-GlcA	$\beta 1 \rightarrow 4$	D-GlcN (S, 6S)
	L-IdoA	$\alpha 1 \Rightarrow 4$	D-GlcN (S)
	L-IdoA (2S)	$\alpha 1 \rightarrow 4$	D-GlcN (S)
	D-GlcA	$\alpha 1 \rightarrow 4$	D-GlcN (S)
Heparina	D-GlcA	$\alpha 1 \rightarrow 4$	D-GlcN (S, 6S)
	L-IdoA (2S)	$\beta 1 \rightarrow 4$	D-GlcN (S)
	L-IdoA (2S)	$\beta 1 \Rightarrow 4$	D-GlcN (S, 6S)

2S: 2-O-Sulfatado; 6S: 6-O-Sulfatado; S: N-Sulfatado

2.4 Proteínas de ligação aos Glicosaminoglicanos (GAGs)

Mais de 100 proteínas de ligação à glicosaminoglicanos (GAGs) foram descritas na literatura, alguns exemplos estão representados na Tabela 4. Uma maior extensão desses estudos está direcionada às interações entre essas proteínas e à heparina e ao heparan sulfato, os quais são altamente sulfatados (ESKO e LINHARDT, 2009).

Tabela 4. Exemplos de proteínas de ligação aos glicosaminoglicanos (GAGs) e a sua atividade biológica. *Fonte: adaptado de Esko e Linhardt, 2009*.

Classe Exemplos		Efeitos fisiológicos e/ou patológicos da ligação	
Enzimas	Enzimas de biossíntese de glicosaminoglicanos, trombina e fatores de coagulação (proteases), proteínas do complemento (esterases), superóxido dismutase extracelular, topoisomerase.	Múltiplos.	
Inibidores enzimáticos	Antitrombina, cofator II da heparina, inibidor da protease dos leucócitos, inibidor de C1 esterase.	Coagulação, inflamação, regulação do complemento.	
Proteínas de adesão celular	P-selectina, a L-selectina, algumas integrinas.	Adesão celular, inflamação, metástase.	
Proteínas da matriz extracelular	Laminina, fibronectina, colágeno.	Adesão celular, organização de matriz.	
Quimiocinas	Fator plaquetário IV, γ -interferon, interleucinas.	Quimiotaxia, sinalização, inflamação.	
Fatores de crescimento	Fatores de crescimento de fibroblastos, fator de crescimento de hepatócitos, fator de crescimento endotelial vascular.	Mitogênese, migração celular.	
Proteínas ligadoras de lipídeos	Apolipoproteínas E e B, lipase lipoprotéica, lipase hepática, anexinas	Metabolismo lipídico, funções da membrana celular.	
Proteínas nucleares	Histonas, fatores de transcrição.	Desconhecido.	
Proteínas de superfície do patógeno	Proteína da malária circunsporozoíto.	Infecções por patógenos.	
Proteínas do envelope viral	Vírus herpes simplex, vírus da dengue, vírus da imunodeficiência humana, vírus da hepatite C.	Infecção viral.	

As chamadas "proteínas de ligação à heparina", como o próprio nome sugere, apresentam uma elevada afinidade em interagir com a heparina, tais como o fator de crescimento de fibroblastos básico (bFGF), fator de crescimento endotelial vascular (VEGF), a fibronectina (FN) e antitrombina (AT). Além disso, a heparina desempenha importante papel na regulação da atividade e estabilidade destas proteínas (ARISAKA et al., 2013). Outros exemplos de proteínas biologicamente ativas que interagem com a heparina, e também com heparan sulfato, são: alguns fatores da coagulação sanguínea, lipases, inibidores enzimáticos, etc. (KARLSSON e WINGE, 2004; GRUNERT et al., 2008). Essas interações desempenham papéis importantes nos processos fisiológicos, bem como nos patológicos (OLAD e NABAVI, 2007).

Os sítios de ligação nas proteínas sempre contêm aminoácidos básicos (Lys e Arg) cujas cargas positivas, provavelmente, interagem com os grupamentos sulfatos e carboxilatos (carregados negativamente) presentes nas cadeias dos GAGs (ESKO et al., 2009). A interação da heparina com a antitrombina foi o primeiro caso relatado de uma interação de significado fisiológico entre a heparina e uma proteína específica (CAPILA e LINHARDT, 2002). Sabese que a heparina liga-se à molécula da antitrombina (Figura 9), aumentando em mais de 1.000 a 2.500 vezes sua função de inibir a cascata da coagulação, através da inibição da formação da trombina. A AT possui uma região central que consiste em 3 folhas-β, α-hélices e ainda uma alça reativa em sua superfície (reactivesite loop). Este local, por sua vez, é onde a antitrombina liga-se à protease-alvo de acordo com o mecanismo de ação das serpinas: resíduos de arginina liga-se covalentemente à serina ou cisteína da protease resultando na formação do complexo intermediário acila, que irá aumentar sua susceptibilidade à proteólise por parte da enzima, facilitando sua depuração (OLSON et al, 2010). Em sua forma latente inativa, a AT circula com seu loop reativo não exposto. Uma vez ligado à heparina, a AT sofre uma mudança conformacional e se transforma em uma forma ativada permitindo a exposição do sítio reativo e assim aumentando sua reatividade (ASMAL et al, 2012).




Figura 9. A – Estrutura da antitrombina; B – Antitrombina complexada com uma sequência pentassacarídica de heparina; C – Sequência pentassacarídica da heparina essencial para ocorrer a interação heparina-AT. *Fonte: http://en.academic.ru/pictures/enwiki/65/Antithrom%2Bheparin.jpeg*

Quando imobilizados, a heparina e o heparan sulfato, em decorrência da semelhança estrutural, podem interagir com fatores da coagulação, funcionando como um ligante de afinidade capaz de interagir com proteínas. Além disso, permitir a troca de cátions de alta capacidade devido à presença de grupos sulfatos aniônicos em sua estrutura (KRAPFENBAUER e FOUNTOULAKIS, 2009).

2.5 Adsorção por afinidade à heparina e ao heparan Sulfato (HS)

Existe uma gama de materiais heparinizados segundo a literatura com diversas aplicações no ramo da biotecnologia. Podemos citar algumas destas publicações: em polidimetilsiloxano (THORSLUND et al, 2005); em enxertos de politetrafluoretileno para cirúrgia vascular (HEYLIGERS et al, 2006); em superfície de polietileno (KONDO et al, 2008); superfície de titânio com heparina revestida (HUH et al, 2011); em dacron e polietileno tereftalato (CHANDY et al, 2000); em matriz de celulose (MURUGESAN et al, 2008); imobilização de heparina em nanopartículas (nanotubos de carbono, óxidos de ferro, sílica, fosfato de cálcio e pontos quânticos) (MURUGESAN et al, 2008; XING et al, 2010). Um outro emprego é verificar a afinidade de ligação entre heparina e proteínas. A heparina imobilizada em suportes sólidos é amplamente utilizada para a purificação de proteínas de ligação a glicosaminoglicanos (MURUGESAN et al., 2008).

Posto isto, a adsorção por afinidade à heparina e ao heparan sulfato é um método bastante utilizado para fracionar ou purificar proteínas e outras substâncias biológicas mediante a interação (afinidade) entre as moléculas de interesse (Figura 10) e esses GAGs imobilizados ao suporte insolúvel (XIONG et al., 2008).




Figura 10. Princípios da adsorção por afinidade.

A heparina já vem sendo utilizada para o isolamento de proteínas plasmáticas e de membrana, sendo a utilização mais frequente o isolamento da antitrombina a partir de plasma humano (JOSIC, 1993). A alta afinidade de ligação da heparina e do heparan sulfato a várias proteínas, incluindo fatores de crescimento e enzimas da coagulação sanguínea, tem sido relacionada com a sua carga líquida negativa em pH neutro (FENG et al., 2004; KAWAKAMI et al., 2006; JOHNSON et al., 2010). Além disso, o uso da adsorção por afinidade à heparina pode ser aplicada como uma estratégia para remover seletivamente algumas proteínas de grande abundância, facilitando a análise de proteínas de baixa concentração no plasma. Já é demonstrado que a albumina pode ser removida, por exemplo, através de técnicas de colunas de imunoafinidade, aprisionamento isoelétrico, adsorção por afinidade, etc. (LEI et al., 2008).

3 Referências

ARAUJO, A.M., NEVES JR, M.T., AZEVEDO, W.M., OLIVEIRA, G.G., FERREIRA, D. L., COELHO, R.A.L., FIGUEIREDO, E.A.P., CARVALHO JR, L.B. Polyvinyl alcohol-glutaraldehyde network as support for protein immobilization. *Biotechnology Techniques*, 11, 67-72, 1997.

ARIAS, J.L., GALLARDO, V., GÓMEZ-LOPERA, S.A., PLAZA, R.D., DELGADO, A.V. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. *Journal of Controlled Release*, 77, 309-321, 2001.

ARISAKA, Y., KOBAYASHI, J., YAMATO, M., AKIYAMA, Y., OKANO, T. Switching of cell growth/detachment on heparin-functionalized thermoresponsive surface for rapid cell sheet fabrication and manipulation. *Journal Biomaterials*, 34 (17), 4214–4222, 2013.

ASMAL M.; WHITNEY J. B.; LUEDEMANN C.; CARVILLE A.; STEEN R.; et al. In vivo Anti-HIV Activity of the Heparin-Activated Serine Protease Inhibitor Antithrombin III Encapsulated in Lymph-Targeting Immunoliposomes. *PLoS ONE*, v. 7, n. 11, p. 01- 15, 2012.

AVIEZER, D., YAYON, A. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. *Proceedings of the National Academy of Sciences*, 91: 12173-12177, 1994.

BARBOSA, A. D., BARROS, F. S. M., CALLOU, E. Q., ALMEIDA, A. M. P., ARAUJO, A. M., AZEVEDO, W. M., CARVALHO JR, L. B. Cellulose acetate as solid phase in ELISA for plague. *Memórias do Instituto Oswaldo Cruz*, 95, 95-96, 2000.

BARBOSA E. F.; MOLINA F. J.; LOPES F. M.; GARCIA-RUIZ P. A.; CARAMORI S. S.; FERNANDES K. F. Immobilization of Peroxidase onto Magnetite Modified Polyaniline. *The Scientific World Journal*, v. 2012, p. 01-05, 2012.

BARROS, A.E.L., ALMEIDA, A.M.P., AZEVEDO, W.M., CARVALHO JR, L.B. Polysiloxane/PVA-glutaraldehyde hybrid composite as solid phase for immunodetections by ELISA. *Brazilian Journal of Medical and Biological Research*, 35, 459-463, 2002.

BICKERSTAFF, G. Immobilization of enzymes and cells. In: Walker JM, editor. **Methods in biotechnology 1**. Totowa, NJ: Humana Press, 1997.

BUCUR, B., DANET, A. F., MARTY, J.M. Versatile method of cholinesterase immobilization via affinity bonds using Concanavalin A applied to the construction of a screen-printed biosensor. *Biosensors and Bioelectronics*, 20, 217-225, 2004.

CABRERA, M.P; MACIEL, J. C; QUISPE-MARCATOMA, J; PANDEY, B; NERI, D.F.M; SORIA, F; BAGGIO-SAITOVITCH, E; CARVALHO, L.B.J; Magnetic composites from minerals: study of the iron phases in clay and diatomite using Mössbauer spectroscopy, magnetic measurements and XRD. *Hyperfine Interactions*. 2013.

CAPILA, I., LINHARDT, R.J. Heparin – Protein Interactions. *Angewandte Chemie International Edition*, 41, 390-412, 2002.

CARAMORI S. S.; FARIA F. N.; VIANA M. P.; FERNANDES K. F.; CARVALHO L. B. Trypsin immobilization on discs of polyvinyl alcohol glutaraldehyde/polyaniline composite. *Materials Science and Engineering C*, v. 31, p. 252–257, 2011.

CARAMORI, S.S., FERNANDES, K. F. Covalent immobilisation of horseradish peroxidase onto poly(ethylene terephtalate)-poly(aniline) composite. *Process Biochemistry*, 39, 883-888, 2004.

CARNEIRO-LEÃO, A.M. A. C., OLIVEIRA, E. A., CARVALHO JR, L. B. Immobilization of protein on ferromagnetic Dacron. *Applied Biochemistry and Biotechnology*, 33, 53-58, 1991.

CHANDY T.; DAS G. S.; WILSON R. F.; ROA G. H. R. Use the plasmaglow for surface-engineering biomolecules to enhance blood compatibility of Dacron and PTFE vascular prosthesis. *Biomaterials*, v. 21, n. 7, p. 699-712, 2000.

CHI, K., HWANG, H.Y., PARK, J.Y., LEE, C.W. Effective dehydrogenative oxidation of amines and alcohols via radical mechanism by nano-porous polyaniline catalysis. *Synthetic Metals*, 159, 26–28, 2009.

COELHO, R.A.L., SANTOS, G.M.P., AZEVÊDO, P.H.S., JAQUES, G. A., AZEVEDO, W. M., CARVALHO JR, L.B. Polyaniline-dacron composite as solid phase in enzyme linked immunosorbent assay for Yersinia pestis antibody detection. *Journal of Biomedical Materials Research*, 56, 257-260, 2001.

COELHO, R.A.L., JAQUES, G.A., BARBOSA, A. D., VELÁSQUEZ, G., MONTENEGRO, S.M.L., AZEVEDO, W.M., CARVALHO JR, L.B. Magnetic polysiloxane-polyvinyl alcohol composite as solid-phase in chemiluminescent assays. *Biotechnology Letters*, 24, 1705-1708, 2002.

COELHO, R. A.L., YAMASAKI, H., PEREZ, E.P., CARVALHO JR, L.B. The use of polysiloxane-polyvinyl alcohol beads as solid phase in IgG anti-Toxocara canis detection using a recombinant antigen. *Memórias do Instituto Oswaldo Cruz*, 98, 391-393, 2003.

ESKO, J.D., LINHARDT, R.J. Proteins that Bind Sulfated Glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, et al., editors. *Essentials of Glycobiology*. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; Chapter 35. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1948/; 2009.

FENG, W., ZHAO, L., WANG, K. Interaction of polysaccharides with interferon-gamma using an improved ELISA approach. *Carbohydrate Polymers*, 58, 89–94, 2004.

FERNANDES, K.F., LIMA, C.S., PINHO, H. Collins, C. H. Immobilization of Horseradish Peroxidase onto Polyaniline Polymers. *Process Biochemistry*, 38:9, 1379, 2003.

GILL, I., BALLASTEIROS, A. Bioencapsulation within synthetic polymers (part 1): sol-gel encapsulated biologicals. *Trends in Biotechnology*, 18, 282-296, 2000.

GUISAN, J. M. Immobilization of enzymes as the 21st century begins, In: Immobilization of enzymes and cells. (second edition), J. M. Guisan, (Ed.), *Humana Press Inc.*, ISBN 1-59745-053-7, New Jersey, 2006.

GODJEVARGOVA, K.G. Immobilization of urease onto chemically modified acrylonitrile copolymer membranes. *Journal of Biotechnology*, 103, 107-111, 2003.

GOLDSTEIN, L., FREEMAN, A., BLASSBERGER, D., Granot, R., Sokolovsky. Biotechnological Applications of Proteins and Enzymes, *Bohak, Z. and Sharon, N., eds., New York*, 156-159, 1977.

GRUNERT M, NURCOMBE V AND COOL SM. Stem cell fate decisions: the role of heparan sulfate in the control of autocrine and paracrine signals. **Curr Stem Cell Res Ther 3**: 1–8. 2008.

HEYLIGERS, J. M. M.; VERHAGEN, H. J. M.; ROTMANS, J. I.; WEETERINGS C.; GROOT, P. G. D.; MOLL, F. L.;LISMAN T. Heparin immobilization reduces thrombogenicity of small-caliber expanded polytetrafluoroethylene grafts. *Journal of vascular surgery*, v. 43, n. 3, p. 587-591, 2006.

HUH J. B.; LEE J. Y.; LEE K. L.; KIM S. E.; YUN M. J.; SHIM J. S.; SHIM J.S.; SHIN S.W. Effects of the immobilization of heparin and rhPDGF-BB to titanium surfaces for the enhancement of osteoblastic functions and anti-inflammation. *The Journal of Advanced Prosthodontics*, v. 3, n. 3, p. 152-160, 2011.

HANSEN, S.U., MILLER, G.J., JAYSON, G.C., GARDINER, J.M. First Gram-Scale Synthesis of a Heparin-Related dodecasaccharide. *Organic Letters*, 15(1), 88-91, 2013.

HAO, R., XING, R.J., XU, Z.C., HOU, Y.L., GAO, S., SUN, S.H. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. *Advanced Materials*, 25, 2729–2742, 2010.

HERMANSON, G.T., MALLIA, A. K., SMITH, P.K. Immobilized affinity ligand techniques. *New York: Academic Press*, Inc, 1992.

JOSIC, D., BAL, F., SCHWINN, H. Isolation of plasma proteins from the clotting cascade by heparin affinity chromatography. *Journal of Chromatography*, 632, 1, 1993.

JOHNSON, D.J.D., LANGDOWN, J., HUNTINGTON, J.A. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7 A structure of the ternary complex. *Proceedings of the National Academy of Sciences*, 107, 645 e 650, 2010.

KANG, Y.S., RISBUD, S., RABOLT, J.F., STROEVE, P. Synthesis and characterization of nanometer-size Fe3O4 and gamma-Fe2O3 particles. *Chemistry of Materials*, 8, 2209–2211, 1996.

KARLSSON, G., WINGE, S. Separation of latent, prelatent, and native forms of human antithrombin by heparin affinity high-performance liquid chromatography. *Protein Expression and Purification*, 33, 339–345, 2004.

KAWAKAMI, A., HIRAYAMA, K., KAWAKAMI, F., KAWAKAMI, H., FUJIHARA, M., OHTSUKI, K. Purification and biochemical characterization of a fibroblast growth factor-binding protein (FGF-BP) from the lactoferrin fraction of bovine milk. *Biochimica et Biophysica Acta*, 1760, 421-431, 2006.

KONDO, S.; FUKUNAGA, Y.;OIKAWA, M.;SASAI, Y.;KUZUYA, M. Plasma-Assisted Immobilization of Heparin onto Low-Density Polyethylene Surface. *Chemical & Pharmaceutical Bulletin*, v.56, n. 7, p. 921-925, 2008.

KONG, F., FUN HU, Y. Biomolecule immobilization techniques for bioactive paper fabrication. *Analytical and Bioanalytical Chemistry*, 403, 1, 7-13, 2012.

KOOPMANN, W., EDIRIWICKREMA, C., KRANGEL, M.S. Structure and function of the glycosaminoglycan binding site of chemokine macrophage – inflammatory protein-1 beta. *Journal of Immunology*, 163: 2120–2127, 1999.

KORECKÁ, L., JEZOVÁ, J., BÍLKOVÁ, Z., BENES, M., HORÁK, D., HRADCOVÁ, O., SLOVÁKOVÁ, M., VIORY, J.L. Magnetic enzyme reactors for isolation and study of heterogeneous glycoproteins. *Journal of Magnetism and Magnetic Materials*, 293, 349-357, 2005.

KRAPFENBAUER, K., FOUNTOULAKIS, M. Improved Enrichment and Proteomic Analysis of Brain Proteins with Signaling Function by Heparin Chromatography. *Methods in Molecular Biology*, 566, 165–180, 2009.

LEI, T., HE, Q.Y., WANG, Y.L., SI, L.S., CHIU, J.F. Heparin chromatography to deplete high-abundance proteins for serum proteomics. *Clinica Chimica Acta*, 388, 173–178, 2008.

LEVER, R., PAGE, C.P. Non-anticoagulant Effects of Heparin: An Overview. *Heparin - A Century of Progress, Springer, Berlin*, 281–306, 2012.

MA, M., ZHANG, Y., YU, W., SHEN, H.Y., ZHANG, H.Q., GU, N. Preparation and characterization of magnetite nanoparticles coated by amino silane. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 212, 219-226, 2003.

MACIEL, J.C., ANDRADE, P.L., NERI, D.F.M., CARVALHO JR, L.B., CARDOSO, C.A., CALAZANS, G.M.T., AGUIAR, J.A., SILVA, M.P.C. Preparation and characterization of magnetic levan particles as matrix for trypsin immobilization. *Journal of Magnetism and Magnetic Materials*, 324, 1312–1316, 2012.

MELO, E.H.M. *Imobilização covalente de enzimas em polietilenotereftalato sob a forma azida*. Dissertação (Mestrado em Bioquímica), Universidade Federal de Pernambuco, Recife, 1984.

MENG, S., LIU, Z., SHEN, L., GUO, Z., CHOU, L.L., ZHONG, W., DU, Q., GE, J. The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. *Journal Biomaterials*, 30, 2276–2283, 2009.

MONTENEGRO, S.M.L., SILVA, J.D.B., BRITO, M.E.F, CARVALHO JR, L.B. Dot enzyme-linked immunosorbent assay (dot-ELISA) for schistosomiasis diagnosis using Dacron as solid-phase. *Revista da Sociedade Brasileira de Medicina Tropical*, 32, 139-43, 1999.

MURUGESAN, S., XIE, J., LINHARDT, R.J. Immobilization of heparin: approaches and applications. *Current Topics in Medicinal Chemistry*, 8, 2, 90-100, 2008.

NADER, H.B., PINHAL, M.A.S., BAÚ, E.C., CASTRO, R.A.B., MEDEIROS, G.F., CHAVANTE, S.F., LEITE, E.L., TRINDADE, E.S., SHINJO, S.K., ROCHA, H.A.O., TERSARIOL, I.L.S., MENDES, A., DIETRICH, C.P. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells. *Brazilian Journal of Medical and Biological Research*, 34, 699-709, 2001.

NERI, D.F.M; BALCÃO, V.M; COSTA, R.S; ROCHA, I.C.A.P; FERREIRA, E.M.F.C; TORRES, D.P.M; RODRIGUES, L.R.M; CARVALHO Jr, L.B; TEIXEIRA, J.A. Galacto-oligosaccharides production during lactose hydrolysis by free Aspergillus oryzae β-galactosidase and immobilized on magnetic polysiloxane-polyvinyl alcohol. Food Chemistry. 115, 92-99, 2009.

NGAMNA, O., MORRIN, A., MOULTON, S.E., KILLARD, A.J., SMYTH, M.R., WALLACE, G.G. An HRP based biosensor using sulphonated polyaniline. *Synthetic Metals*, 153:1-3, 185, 2005.

OLAD, A., NABAVI, R. Application of polyaniline for the reduction of toxic Cr(VI) in water. *Journal of Hazardous Materials*, 147:3, 845, 2007.

OLSON S. T.; RICHARD B.; IZAGUIRRE G.; SCHEDIN-WEISSS.; GETTINS P. G. W. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. a

paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. *Biochimie*, v. 92, n. 11, p. 1587–1596, 2010.

PINHEIRO, S.M.P., CARVALHO JR, L.B., CHAVES, M.E.C. The use of ferromagnetic dacron as solid-phase in chemiluminescent assays. *Biotechnology Techniques*, 13, 919-922, 1999.

PETITOU, M., CASU, B., LINDAHL, U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. *Biochimie*, 85, 83-89, 2003.

QU, S.C., YANG, H.B., REN, D.W., KAN, S.H., ZOU, G.T., LI, D.M. Magnetite nanoparticles prepared by precipitation from partially reduced ferric chloride aqueous solutions. *Journal of Colloid and Interface Science*, 215, 190–192, 1999.

RODGERS, G M. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. **Thrombosis Haemostasis**, v. 101, n. 5, p. 806–812, 2009.

SAMPAIO, L., TERSARIOL, I., LOPES, C., BOUÇAS, R., NASCIMENTO, F., ROCHA, H., NADER, H. Heparins and heparans sulfates. Structure, distribution and protein interactions. In: Verli h (ed), insights into carbohydrate structure and biological function. *Transworld Research Network, Kerala*, 1-24, 2006.

SASISEKHARAN, R., SHRIVER, Z., VENKATARAMAN, G., NARAYANASAMI, U. Roles of heparan-sulphate glycosaminoglycans in cancer. *Nature Reviews Cancer*, 2: 521–528, 2002.

SINGH, S., SOLANKI, P.R., PANDEY, M.K., MALHOTRA, B.D. Covalent immobilization of cholesterol esterase and cholesterol oxidase on polyaniline films for application to cholesterol biosensor. *Analytica Chimica Acta*, 568:1-2, 126, 2006.

SRIVASTAVA, G.K., SRIVASTAVA, P.C. Origin and evolution of heterosporous lycopods. *Phytomorphology Golden Julibee*, 499-527, 2001.

THORSLUND, S.; SANCHEZ, J.; LARSSON, R.; NIKOLAJEFF, F.; BERGQUIST J. Bioactive heparin immobilized onto microfluidic channels in poly(dimethylsiloxane) results in hydrophilic surface properties. *Colloids and Surfaces. B, Biointerfaces*, v. 46, n. 4, p. 106–113, 2005.

TWEEDDALE, H. J., REDMOND, J.W. Binding of carbohydrates to solid supports Part 3: Reaction of sugar hydrazones with polystyrene substituted with aromatic aldehydes. *Glycoconjugates Journal*, 15, 847-854, 1998.

VISKOV, C., ELLI, S., URSO, E., GAUDESI, D., MOURIER, P., HERMAN, F., BOUDIER, C., CASU, B.; TORRI, G., GUERRINI, M. Heparin Dodecasaccharide containing two antitrombin binding pentasaccharides. Structural features and biological properties. *Journal of Biological Chemistry*, published online July 10, 2013.

WEETALL, H. H. Insolubilized L-asparaginase Implant: A preliminary report. *Journal of Biomedical Materials Research*, 4, 597-599, 1970.

WEETALL, H.H., LEE, M.J. Antibodies immobilized on inorganic supports. *Applied Biochemistry and Biotechnology*, 22, 311-330, 1989.

WU, W., HE, Q.G., JIANG, C.Z. Magnetic iron oxide nanoparticles: synthesis and surface functionalization strategies. *Nanoscale Research Letters*, 3, 397–415, 2008.

WUNDERBALDINGER, P., JOSEPHSON, L., WEISSLEDER, R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. *Bioconjugate Chemistry*, 13, 264–268, 2002.

XING Z. C.; CHANG Y.; KANG I. K. Immobilization of biomolecules on the surface of inorganic nanoparticles for biomedical applications, *Science and technology Advanced Materials*, v. 11, n. 1, p. 1-17, 2010.

XIONG, S., ZHANG, L., HE, Q.Y. Fractionation of Proteins by Heparin Chromatography; 2D PAGE: Sample Preparation and Fractionation. *Methods in Molecular Biology*TM, 424, 213–221, 2008.

YAMAURA, M., CAMILO, R.L., SAMPAIO, L.C., MACEDO, M.A., NAKAMURA, M., TOMA, H.E. Preparation and characterization of (3-aminopropyl) triethoxysilane-coated magnetite nanoparticles. *Journal of Magnetism and Magnetic Materials*, 279, 210-217, 2004.

YE X.; WANG H.; ZHOU J.; LI H.; LIU J.; The Effect of Heparin-VEGF Multilayer on the Biocompatibility of Decellularized Aortic Valve with Platelet and Endothelial Progenitor Cells. *PLoS ONE*, v. 8, n. 1, 2013.

4 Objetivos


4.1 Objetivo Geral

Propor derivados magnéticos de heparina e heparan sulfato com vistas à obtenção de uma matriz de afinidade para purificação de proteínas do plasma.

4.1 Objetivos específicos

- Sintetizar as partículas magnéticas;
- Imobilizar heparina às partículas de PET ferromagnético e magnetita revestida com PANI;
- Determinar a quantidade de heparina e heparan sulfato fixadas às matrizes;
- Caracterizar as partículas magnéticas por análises biológicas, e físico-químicas;
- Utilizar o derivado para separar/purificar proteínas do plasma.
- Identificar as proteínas purificadas.
- Realizar testes in vitro com as proteínas purificadas mediante suas funções biológicas específicas.

5 Artigo a ser submetido à revista internacional "Biomaterials"



Título: Ferromagnetic Polyethyleneterephthalate (PET) covered with heparin for affinity separation of antithrombin

Autores: R.S. Silva, A.A.D. Merces, G.B. Oliveira, L.B. Carvalho Jr.

Ferromagnetic Polyethyleneterephthalate (PET) covered with heparin for affinity separation of antithrombin

R.S. Silva¹, A.A.D.Merces¹, G.B. Oliveira², L.B. Carvalho Jr^{1*}

¹Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco; ²Centro de Ciências da Saúde, Universidade Federal do Recôncavo, Bahia.

* Corresponding Author:

Luiz Bezerra de Carvalho Júnior

Laboratório de Imunopatologia Keizo Asami (LIKA)

Departamento de Bioquímica, Universidade Federal de Pernambuco

Rua Professor Moraes Rego, 1235 Cidade Universitária, Recife - PE

CEP 50670-901

Telephone number: +55 81 2126.8484

Fax: +55 81 2126.8485

e-mail: lbcj@hotlink.com.br

Abstract

This work describes the use of ferromagnetic Dacron (polyethyleneterephthalate; PET) coated with heparin for antithrombin purification (affinity binding). PET film was converted to PET-hydrazide powder by methanolic hydrazine hydrate and magnetized by thermal coprecipitation of ferric and ferrous chlorides. Heparin was activated by carbodiimide and N-hydroxysuccinimide and coupled to the magnetic support. The magnetic derivatives remained stable for 24 months demonstrating its stability even after 10 reuses. Elemental and Infrared spectra analyses presented evidences of heparin immobilization. Electrophoresis revealed bands with molecular mass 58 kDa corresponding to that referred to antithrombin. Moreover, laboratory tests detected a low activity of antithrombin in plasmas that were tested by affinity assay to heparin and delay clotting time of plasmas that came into contact with the eluted fractions containing antithrombin. Therefore, the results presented confirm the success of immobilization and affinity separation process.

Keywords: antithrombin, Dacron, heparin, immobilization, polyethyleneterephthalate

1. Introduction

Affinity separation is one of the most powerful techniques in selective purification and isolation of a great number of compounds [1]. This technique has the purification power to eliminate steps, increase yields and improve process economics [2]. Heparin chromatography is an adsorption chromatography in which molecules to be purified are specifically and reversibly adsorbed by heparin immobilized on an insoluble support [3]. In general, heparin chromatography is a method of affinity chromatography used to purify or fractionate biological substances that can interact with heparin. This method has been extensively developed following the progress of chromatographic supports and technologies.

In our laboratory, Dacron or polyethyleneterephthalate, also known as PET and widely used as plastic vessel, has been proposed as a support for biomolecules immobilization [4, 5].

Heparin is a biologically important and chemically unique polysaccharide, widely recognized as an anticoagulant drug. Many studies have demonstrated that heparin has the ability to bind a wide range of biomolecules, including serine protease inhibitors (especially of antithrombin) [6].

In the present study, heparin was immobilized on ferromagnetic PET and used as affinity matrix for purification of antithrombin.

2. Material and methods

2.1. Materials

The Dacron (polyethyleneterephthalate) were donated by Terphane Ltda (Cabo de Santo Agostinho, PE, Brazil). Heparin was purchased from Cristália Chemicals & Pharmaceuticals Ltda. Carbodiimide(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; EDAC), N-hydroxysuccinimide (NHS) and hydrazine hydrate were purchased from Sigma-Aldrich Ltda, whereas ferric and ferrous chlorides were from Merck SA. The activated partial thromboplastin time (aPTT) kit was acquired from Labtest Diagnóstica.

2.2. Ferromagnetic PET-hydrazide synthesis

Films of PET (4g) were cut in strips and incubated in methanol (100 mL) containing hydrazine hydrate (10 mL) at 40° C for 16 h with stirring. Afterwards the PET-hydrazide (white powder) was washed twice with methanol. The suspension of PET-hydrazide (2 g in 100 mL of water) was allowed to sedimentfor 10 min and the supernatant was decanted to

remove fines (five times). Finally, the material was filtered and oven-dried (40°C) homogenized and sieved (250μm).

PET-hydrazide (2g) was stirred in deionized water (100 mL) and an aqueous solution (10mL) containing FeCl₃.6H₂O (300mg) and FeCl₂.4H₂O (121mg) was added dropwise. The pH and temperature of this mixture were raised up to 11 (with 28%, v/v, NH₄OH) and 100°C, respectively, and kept for 30 min with stirring. Lastly, ferromagnetic PET-hydrazide (mPET) also was filtered, oven-dried (40°C), homogenized and sieved (250μm).

2.3. Heparin immobilization on ferromagnetic PET-hydrazide (mPET).

N-hydroxysuccinimide (60 mg) and carbodiimide (100 mg) were added to a heparin solution (36 mg in 12 mL) and the solution pH was maintained between 4.5 and 5.0 for 30 min. An aliquot of this mixture (1 mL) was incubated with the mPET (30 mg) for 16 h with mild stirring to form the derivative mPET-HEP (heparin immobilized on ferromagnetic PET). Particles were recovered under a magnetic field (6,000Oe) and washed ten times with deionized water to remove non-immobilized heparin. The supernatants were washed and reserved for heparin determination. Magnetic products were stored in water for 2 years at 4°C for use in two stages: start (time zero) and final (24th month) to study the stability of the support in the purification of antithrombin.

2.4. Heparin determination.

Heparin was determined in accordance with the methodology proposed by Oliveira et al. [7]. This method is based on the property of heparin to form complexes with basic dyes such as methylene blue (MB). The dye was prepared with 30 mg of MB in 1 L 0.01N HCl containing 0.2% NaCl. The sample (1 mL) was added to the MB solution (2.5 mL) and the volume was completed to 17.5 mL with water. The mixture was stirred and left to stand for 5 min. Absorbance was measured at 664 nm. The calibration curve was constructed using heparin concentrations from 10 to 100 mg/mL. The immobilized heparin was established by adding MB solution (1 mL) to the mPET-HEP (30 mg) and kept for 5 min under mild stirring. The magnetic particles were collected and the absorbance of the supernatant read at 664 nm. The mPET (30 mg) was used as control. These procedures were repeated four times to evaluate the MB adsorption by support.

2.5. Physical-chemical analysis

Infrared spectra and elemental composition of the magnetite, PET-hydrazide, mPET and mPET-HEP, all after 24 months of use, were carried out by using, respectively, a BRUKER instrument model IFS 66 and CHNS-O Carlo Erba model EA 1110. These analyses were made in the Central Analytical of the Departamento de Química Fundamental, Universidade Federal de Pernambuco, Brazil.

2.6. Antithrombin purification.

To 30 mg of mPET-HEP matrix was added 1 mL of citrated human plasma. This mixture was kept under mild stirring for 45 minutes at 25°C. The magnetic particles were collected by the magnetic field and the supernatant was discarded. The magnetic particles were washed with 0.01 M phosphate buffer, pH 7.4, until no absorbance at 280 nm was detected. Subsequently the magnetic particles were incubated with the buffer containing increasing concentrations of NaCl (0.25M; 0.5M, and 1.0 M). The incubation and elution procedures were repeated five times to increase the total mass of proteins to enable the polyacrylamide gel electrophoresis analysis according to Laemmli [8]. For these tests, were used magnetic products prepared at time zero and those stored at 2 years.

2.7. Anticoagulant activity

Fifty milligrams of the mPET-HEP and mPET (control) were incubated under mild stirring with 400 μ L of 0.15 M NaCl and 500 μ L of plasma at 37° C. After 5 min, 100 μ L of 1%, w/v CaCl₂ was addedand the time to onset of fibrin registered.

The antithrombotic activity of eluted fractions was performed consisting of the first pre-incubation of plasma in the magnetic particles with and without heparin, after the thrombin with its inhibitor (fresh plasma added antithrombin eluted with 1.0 M NaCl). The residual activity of antithrombin was measured by automated chromogenic method (action amidolytic on the substrate Tos-Gly-Pro-Arg-ANBA-IPA), reading the absorbance at 405nm. Activated partial thromboplastin time (aPTT) was performed by adding 20 µL of eluate obtained with the gradient 1.0 M to the reaction system kit. All of these coagulation tests were repeated ten times intercalating each successive use with buffer washing (10 mM PBS pH 7.2) fifty times. Magnetic derivatives synthesized at time zero and after 2 years were also analyzed for these tests ten times.

3. Results

3.1. Yield of immobilization of heparin

Approximately 30 μ g of heparin were immobilized in each mg of support for a period of 16h of hydrazinolysis. This corresponds to a rate of approximately 52% of heparin was incubated for support was immobilized.

3.2. Adsorption of heparin with methylene blue (M.B.)

Table 1 presents the results of adsorption of methylene blue dye for support and its derivative containing heparin. The adsorption of the dye was greater for the derivative of detention, which supports the presence of heparin. It is observed that even after four reuses, there is still a relatively large adsorption compared to the control.

Reuse Number Derivatives (Abs. at 664 nm) 1st $2^{\overline{nd}}$ 4th 3rd 0.818 0.900 1.107 **mPET** 1.075 mPET-HEP 0.195 0.247 0.319 0.324 MB (19.1 μM) 1.331

Table 1. Methylene blue (MB) adsorption on derivatives*

3.3. Assignment of infrared absorption bands

In Figure 1, can observe that the infrared spectrum of the derivative containing heparin showed a pattern of bands in the region between 1700 and 1500 cm⁻¹, and this may indicate that the immobilization procedure was successful. In this region of the spectrum we can point to the amide I bands (1650 cm⁻¹) and amide II (1544 cm⁻¹) (arrows), which may represent the amide group formed by linking the carboxyl group of heparin with the hydrazide group support. The hydrazides of the support groups also have bands of amide I and amide II, however, at different location and intensities. Furthermore, it should be noted that the band seen around 3300 cm⁻¹ in the spectrum of support was not viewed in the derivative of immobilization. This band is produced by the NH₂ group of the hydrazide and its absence can demonstrate that these groups were consumed in the reaction of immobilization.

^{*}The derivatives were incubated with 1mL of 19.1µM MB for 5 minutes under stirring, afterwards the supernatants absorbance were read at 664 nm.




Figure 1: Infrared spectra of derivatives. In ascending order: magnetite; PET-hydrazide; mPET and mPET-HEP. 1: Band of NH₂ group of the hydrazide; 2: Band of amide I; 3: Band of amide II.

3.4. Elemental composition of the derivatives

The elemental composition of the derivatives obtained can be seen in Table 2. In both derivatives, hydrazide-Dacron and this support with immobilized heparin were found the elements C, H and N. It was also observed a 2% difference between the nitrogen and the support that the derivative of detention. There was also a reduction in the content of carbon and nitrogen.

Table 2. Elemental composition of derivatives

Element	Derivatives	
	mPET	mPET-HEP
C	36.37%	35.85%
Н	3.65%	3.74%
N	7.99%	6.03%

3.5. *Electrophoresis*

Figure 2 shows two electrophoresis carried out from the magnetic derivatives mPET-HEP and mPET (control). Columns 1.0 M and 1.0 M* (derivative eluted with 1.0 M NaCl at time zero and stored for 24 months respectively), it is possible to observe the presence of a band corresponding to antithrombin 58 kDa (arrows). This fact is not observed in support that does not contain immobilized heparin. Furthermore, the bands in the fractions eluted with 0.5 M NaCl (at time zero and 24 months stored) of mPET-HEP support are more emphasized than in the control indicating a larger amount of proteins adsorbed on the support containing heparin.




Figure 2: Electrophoresis of protein fractions of plasma obtained with the use of magnetic particles. Elutions were carried out using increasing NaCl concentrations (0.25; 0.5 and 1.0 M) in the magnetic derivatives: a) mPET-HEP and b) mPET (control). AT: Standard Antithrombin. *Elutions performed in supports stored for 24 months. Arrows: Antithrombin (58 kDa).

3.6. Anticoagulant/antithrombotic activity

The Table 3 shows the anticoagulant/antithrombotic activity of the magnetic derivatives. The plasma added to the magnetic particles with immobilized heparin did not coagulate. However the plasmas that were incubated with support without heparin were clotted in less than 4 min.

Sample	Clotting Time	
Sample	(min)	
Plasma control	4.0 ± 0	
mPET	$3,0 \pm 1$	
mPET-HEP	n.c.	

Table 3. Anticoagulant/antithrombotic activity of magnetic particles*.

*30 mg of particles were incubated with 400 μ L of saline (NaCl 0.15 M) added to 500 μ L of plasma in a water bath at 37°C. After temperature stabilization, 100 μ L of calcium chloride 1% was added and the time to onset of fibrin registered. * Independent samples / triplicate. N.C. - Not coagulated during the time observed (>5 h).

Moreover, was detected a low activity of antithrombin in plasmas that were assayed by test of affinity to heparin at time zero and after 24 months of storage. As presented in Figure 3, this activity is still present after ten reuses of magnetic derivative.




Figure 3: Activity of antithrombin present in fresh plasma and after direct contact with the support: a) immediately synthesized (time zero) and b) 24 months stored at 4°C.

The Figure 4 shows a higher value of aPTT in fresh plasmas which have received a portion of eluate 1.0 M when compared to the control. Wherefore, the influence of the

purified antithrombin is also observed when the same support (at time zero and after 24 months of storage) is reused ten times.




Figura 4: Activated partial thromboplastin time (aPTT) of fresh plasma performed by adding small aliquot of the eluate (1.0 M) of magnetic derivatives: a) Immediately synthesized (time zero) and b) 2 years stored at 4°C.

4. Discussion

Heparin chromatography is a powerful technology for separating various target biomolecules and has been widely used to fractionate proteins from the extract of prokaryotic organism or eukaryotic cells [9, 10].

In this study heparin was immobilized on the proposed matrix to purify plasma proteins, especially antithrombin. These quantities of immobilized heparin are comparable to those described in the literature, disregarding the differences between the methods of restraint that were used [11, 12, 13]. However, Funahashi et al. (1982) [14] obtained a level of 16 µg of heparin per mg of wet gel (Sepharose-4B modified to contain amine groups) also using as a coupling agent EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide). A sign of immobilization can be observed by the interaction between heparin and methylene blue dye as it is known that basic dyes such as methylene blue, form complexes with this polymer [7]. Even after successive reuses was still a significant adsorption. This feature can be important for applications in the treatment of effluents from textile industries. Magnetic nanoparticles were coated with polyacrylic acid in order to adsorb methylene blue [15] and the authors observed that these particles were quick and efficient in the adsorption of dye from aqueous solutions.

Infrared spectra of the three constituent particle magnetite, Dacron-hydrazide and heparin have been described in the literature. Yamaura et al. (2004) [16], observed strong bands around 632 cm⁻¹ and 585 cm⁻¹ in their magnetic nanoparticles and attributed to the presence of magnetite. Similar spectra were published by Ma et al. (2003) [17] and Peng et al. (2004) [18]. Obtaining terephthalehydrazide from polyethylene terephthalate (PET) as a method of recycling of plastic was described by Yamaya et al. (2002) [19]. These authors described the band in 3330, 1630 and 1540 cm⁻¹ and characteristics of dihydrazide obtained from the PET. The infrared spectra shown in Figure 1 does not denote any band characteristic of heparin, probably because they were overlapped by bands of PET-hydrazide. Infrared heparin should present bands around 3400, 1624, 1425 and 1236 cm⁻¹ [7].

In all derivatives were found the elements C, H and N as expected, because both the mPET as well as this support with immobilized heparin have these elements. An indication that the immobilization occurred, is the C: N ratio of support (4.55) which is smaller than that for heparin (10.0) [20, 21, 22] and the relationship found for the derivative containing heparin was higher (5.94) than the support. The reduction in the content of carbon and nitrogen and this may be due to immobilization of heparin, which has a lower amount of carbon relative to its support. And this is due to the presence of a large content of oxygen and sulfur in this polysaccharide.

Electrophoresis in polyacrylamide gel with sodium dodecyl sulfate was performed in an attempt to identify possible proteins adsorbed by the mPET-HEP. The main focus was antithrombin, because as we know, it specifically binds heparin with a Kd approximately 20 nM [23] and has many of its features fully described in the literature [24], which would facilitate the study. It is known that antithrombin has a molecular mass of 58 kDa and that in Figure 2 it is represented as a band just below the albumin (66kDa) represented by this band. Thesedata can be seen in both the derivative sused immediately (time zero) and those that were just used two years after stocked. Thus, these experiments showed that protein adsorption occurs and that these were eluted with 1.0 M NaCl even after 2 years of storage.

The Table 3 showed the capacity of the magnetic support containing heparin to prevent clots formation. The literature is replete with efforts to improve blood compatibility of surfaces after immobilization of heparin [25. 26]. This should acquire biocompatibility to the anticoagulant properties of heparin, its interaction with antithrombin and the consequent inhibition of proteases of the cascade of blood coagulation.

Thus, the PET with heparin immobilized may be an important tool for the purification of antithrombin and have an excelente stability even kept for 2 years as shown in Figure 3 and 4, in which there is a significant reduction in activity of this inhibitor of serine protease in the plasma after its incubation to support. It was also noted that the fresh plasma samples that received a small portion of the purified antithrombin by Dacron with immobilized heparin presented a high aPTT compared to control (Figure 4), result of delay the clotting time by inhibiting thrombin. Furthermore, the antithrombin that was separated from plasma remaining active, when it was subjected to affinity chromatography to heparin.

5. Conclusion

The data presented confirm the presence of heparin in Dacron magnetic particle obtained, and the presence of the hydrazide group, essential for the covalent immobilization proposed in this paper. Therefore, these results, coupled with an efficient absorption of methylene blue, confirm successful immobilization of heparin. Finally, the results, even after 2 years stored, demonstrate the efficiency of magnetic separation of antithrombin.

Acknowledgements

The authors thank CNPq for financial support. Terphane, Inc., Cabo, Brazil, is also thanked for providing the Dacron.


7. References

- [1]. Tozzi C, Anfossi L, Giraudi G. J. Chromatogr. B, 2003; 797, 289.
- [2]. Labrou NE. J. Chromatogr. B, 2003; 790, 67.
- [3]. Farooqui, A.A. (1980) Purification of enzymes by heparin-sepharose affinity chromatography. *J. Chromatogr.* 184, 335–345.
- [4]. Carvalho Jr. LB, Silva MPC and Melo EHM. Activity of immobilized alpha-amylase. Braz. J. Med. Biol. Res. 1987; 20: 521-526.
- [5]. Carneiro-Leão AMA, Carvalho Jr. LB and Malagueño E. The use of ferromagnetic Dacron as solid-phase in enzyme immunoassays. Mem. I. Oswaldo Cruz. 1994; 89: 189-193
- [6]. Karlsson, G., Winge, S. Separation of latent, prelatent, and native forms of human antithrombin by heparin affinity high-performance liquid chromatography. *Protein Expr. Purif.* 2004; 33, 339–345.

- [7]. Oliveira, G. B., Carvalho, Jr., L. B.; Silva, M. P. C. Properties of carbodiimide treated heparin. Biomaterials, 2003; v. 24, p. 4777-4783.
- [8]. Laemmli, U. K. Cleavage of structural proteins during the assembly of head of bacteriophageT4. Nature, 1970; v. 227, p. 680-685.
- [9]. Marques MA, Espinosa BJ, Xavier da Silveira EK, et al. Continued proteomic analysis of Mycobacterium leprae subcellular fractions. Proteomics 2004; 4:2942–53.
- [10]. Srivastava PN, Farooqui AA. Heparin-sepharose affinity chromatography for purification of bull seminal-plasma hyaluronidase. Biochem J 1979;183:531–7.
- [11]. Chen, L.; Guo, C.; Guan, Y.; Liu, H. Is of lactoferrin from acid whey by magnetic affinity separation. Separation and Purification Technology, 2007; v. 56, p. 168-174.
- [12]. Björklund, M. & Hearn, M. T. W. Synthesis of silica-based heparin-affinity adsorbents. Journal of Chromatography A, 1996; v. 728; p 149-169.
- [13]. Denizli, A.; & Piskin, E. Heparin-immobilized polyhydroxyethylmethacrylate microbeads for cholesterol removal: a preliminary report. Journal of Chromatography, 1995; v. 670, p. 157-161.
- [14]. Funahashi, M.; Matsumoto, I.; Seno, N. Preparation of three types of heparin-sepharose and their binding activities to thrombin and antithrombin III. Analytical Biochemistry, 1982; v. 126, p. 414-421.
- [15]. Mak, S.-Y. & Chen, D.-H. Fast adsorption of methylene blue on polyacrylic acid-bound iron oxide magnetic nanoparticles. Dyes and Pigments, 2004; v. 61, p. 93-98.
- [16]. Yamaura, M.; Camilo, R. L.; Sampaio, L. C.; Macedo, M. A.; Nakamura, M.; Toma, H. E. Preparation and characterization of (3-aminopropyl) triethoxysilane-coated magnetite nanoparticles. Journal of Magnetism and Magnetic Materials, 2004; v. 279, p. 210-217.
- [17]. Ma, M.; Zhang, Y.; Yu, W.; Shen, H.-Y.; Zhang, H.-Q.; Gu, N. Preparation and characterization of magnetite nanoparticles coated by amino silane. Colloids and Surfaces A: Physicochem. Eng. Aspects, 2003; v. 212, p. 219-226.
- [18]. Peng, Z. G.; Hidajat, K.; Uddin, M. S. Adsorption of bovine serum albumin on nanosized magnetic particles. Journal of Colloid and Interface Science, 2004; v. 271, p. 277-283.
- [19]. Yamaya, M.; Hashime, T.; Yamamoto, K.; Kosugi, Y.; Cho, N.; Ichiki, T.; Kito, T. Chemical recycling of poly(ethylene terephthalate). 2. Preparation of terephthalohydroxamic acid and terephthalohydrazide. Industrial and Engineering Chemistry Research, 2002; v. 41, p. 3993-3998.

- [20]. Griffin, C. C.; Linhardt, R. J.; Van Gorp, C. L.; Toida, T.; Hileman, R. E.; Schubert II, R. L.; Brown, S. E. Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. Carbohydrate Research, 1995; v. 276, p. 183-197.
- [21]. Danishefsky, I.; & Siskovic, E. Heparin derivatives prepared by modification of the uronic acid carboxyl groups. Thrombosis Research, 1972; v. 1, p. 173-182.
- [22]. Burson, S. L.; Fahrenbach, M. J.; Frommhagen, L. H.; Riccardi, B. A.; Brown, R. A.; Brockman, J. A.; Lewry, H. V.; Stokstad, E. L.Isolation and Purification of Mactins, Heparin-like Anticoagulants from Mollusca. Journal of the American Chemical Society, 1956; v. 78, p. 5874-5878.
- [23]. Capila, I. & Linhardt, R. J. Heparin Protein Interactions. Angewandte Chemie International Edition, 2002; v. 41, p. 390-412.
- [24]. Biescas, H.; Gensana, M.; Fernandez, J.; Ristol, P.; Massot, M.; Watson, E.; Vericat, F. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained throught affinity chromatography. Haematologica, 1998; v. 83, p. 305-311.
- [25]. Lin, D.-J.; Lin, D.-T.; Young, T.-H.; Huang, F.-M.; Chen, C.-C.; Cheng, L.-P. Immobilization of heparin on PVDF membranes with microporous structures. Journal of Membrane Science, 2004; v. 245, p. 137-146.
- [26]. Wang, X. H.; Li, D. P.; Wang, W. J.; Feng, Q. L.; Cui, F. Z.; Xu, Y. X.; Song, X. H. Covalent immobilization of chitosan and heparin on PLGA surface. International Journal of Biological Macromolecules, 2003; v. 33, p. 95-100.

6 Artigo a ser submetido à revista internacional "Reactive and Functional Polymers"



Título: Antithrombin purification by affinity matrix using magnetite coated with polyaniline

Autores: Ricardo Souza Silva; Aurenice Arruda das Merces; Givanildo Bezerra Oliveira e Luiz Bezerra Carvalho Jr.

Antithrombin purification by affinity matrix using magnetite coated with polyaniline

Ricardo Souza Silva^a, Aurenice Arruda das Merces^a, Givanildo Bezerra Oliveira^b, Luiz

Bezerra Carvalho Jr.^{a*}

^aLaboratório de ImunopatologiaKeizoAsami, Universidade Federal de Pernambuco, Cidade Universitária, 50670-901 Recife, PE, Brazil

^bCentro de Ciências da Saúde, Universidade Federal do Recôncavo, Centro, 44380-000 Cruz das Almas, BA, Brazil

* CorrespondingAuthor:

Luiz Bezerra de Carvalho Júnior Laboratório de ImunopatologiaKeizoAsami (LIKA) Departamento de Bioquímica, Universidade Federal de Pernambuco Rua Professor Moraes Rego, 1235 Cidade Universitária, Recife - PE CEP 50670-901

Telephone number: +55 81 2126.8484

Fax: + 55 81 2126.8485

e-mail: lbcj@hotlink.com.br

Abstract

Heparin is widely used as a matrix for affinity purification of proteins, mainly of antithrombin. For this reason, the magnetite (MAG) was coated with PANI. Heparin activated with carbodiimide and N-hydroxysuccinimide was incubated for support to occur immobilization. 37% of heparin was retained to support and this matrix magnetic remained stable for 2 years even after 10 reuses. In the process of leaching of plasma proteins, when added 1.0 M NaCl, there is a protein peak to 280 nm in the two forms of magnetite: treated with heparin (MAG-HEP) and coated with PANI (mPANI-HEP). Electrophoresis of these proteins revealed a band corresponding to that referred to the antithrombin (58kDa). This occurred using these two forms of magnetite, but with lower intensity in preparations using HEP-MAG than that coated with PANI. Moreover, alow activity of antithrombin and delay clotting time of plasmas that were exposed to the eluted fractions containing antithrombin was reported especially insupport mPANI-HEP although the MAG-HEP was also noted. Thus these results show the need of PANI for the immobilization of heparin and use this as a support for the purification of antithrombin.

Keywords: antithrombin; heparin; immobilization; polyaniline; separation

1. Introduction

Heparin has been used for some time in the purification of plasma proteins. However, its use is more frequent in the isolation of antithrombin in human plasma by affinity chromatography to heparin [1] which is a valuable technique for the purification of many proteins from human plasma.

Magnetic fields have been utilized in support systems for the study of different immobilized biomolecules [2, 3]. The advantages of small magnetic particles for immobilization in bioprocesses are: improvement of the mass transfer properties of immobilized enzymes suspended in a viscous solution, in which the promotion of mass transfer by agitation is difficult [2]; reuse and easy separated from reaction medium by applying a magnetic field [4] and reduction of the capital and operation costs [5].

The polyaniline (PANI) is a class of polymers highly promising, due to its low cost of synthesis, low grade difficulty of handling and also to present the property to conduct electrons [6]. Depending on the conditions of synthesis, the polymer can act as a semiconductor [7]. Due to the versatility of this polymer, the PANI has been proposed different applications: construction of large capacitors [8], sensors for detection of ammonia [9], remediation for reduction of heavy metals [10], and as a matrix for immobilization of enzymes [11, 12, 13].

In this paper a support is investigated to obtain an array of magnetic based heparin aiming at the purification of antithrombin: magnetic particles coated with polyaniline (PANI) so that heparin was covalently immobilized to the organic polymer.

2. Material and methods

2.1. Production of magnetite and coating with PANI

A magnetic matrix synthesis was conducted as follows: 10 ml of a solution of ferric chloride (1.1 M) and ferrous chloride (0.6 M), both from Sigma Chemical Company, in a 2:1 ratio, was combined with 50 ml of water and adjusted to pH to 11 with ammonium hydroxide [14]. The mixture was heated at 100°C under vigorous stirring for 30 min. The precipitated black (magnetite: MAG) obtained was washed thoroughly with water to remove excess of ammonium hydroxide. The material was then filtered and oven dried, screened and homogenized in sieveopening 250µm.

The magnetic particles (30 mg) were treated with 1.0 mL of ammonium persulfate 0.61 M (APS; Sigma) prepared in 2.0 M HCl, which was under gentle shaking for 30 minutes at 25°C and after successive washes with 10 Mm PBS pH 7.2 were made. In some magnetic support treated with ammonium persulfate (APS) was subsequently incubated with 1.0 ml 0.44 M aniline (Sigma; 99%) for 60 minutes at 4°C to obtain magnetite coated with polyaniline support (mPANI).

2.2. Immobilization of heparin on the magnetic particles

To a solution of heparin (Cristália) 3mg/mL was added N-hydroxysuccinimide (NHS; Sigma) and carbodiimide (EDAC; Sigma). Kept the solution pH between 4.5 and 5.0 for 30 minutes or until there was no increase in pH. Some supporters were not treated to see the importance of activation with EDAC/NHS. These mixtures (1.0 mL) was incubated for 72 hours with 30 mg: a) magnetite (MAG) as control to obtain heparin adsorbed (MAG-HEP); and b) magnetite coated with PANI (mPANI) with a view to obtaining the magnetic particles coated with polyaniline containing heparin covalently attached (mPANI-HEP). These magnetic products were stored in the water for 24 months at 4°C for use in two stages: start (time zero) and final (24th month) to study the stability of the support in the purification of antithrombin.

2.3. Determination of heparin

Heparin and washed was determined in accordance with the methodology used by Oliveira et al. [15]. The method is based on the property of heparin to form complexes with basic dyes such as methylene blue proceeding to reading at 664nm.

2.4. Separation/purification of plasma proteins

To 30 mg of matrix with PANI containing heparin (mPANI-HEP) was added 1.0 mL of citrated human plasma. This mixture was kept under stirring for 1 h at 4°C. Then, with the help of a magnetic field of 6000 Oe, the supernatants were collected and washed out with phosphate buffer 0.01 M pH 7.4, subsequently, the matrix was eluted with buffer containing an increasing gradient of NaCl (0.25 M; 0,5 M; 1.0 M and 2.0 M). These eluates were analysed by polyacrylamide gel electrophoresis according to Laemmli [16]. For these assays, were used magnetic products prepared at time zero and those stored at 24 months.

2.5. Measurement of antithrombin activity

The activity of antithrombin was performed using three forms of magnetite: mPANI-HEP; MAG-HEP and pure magnetite (MAG). Fifty milligrams of these magnetic derivatives were incubated under mild stirring with 400 μ L of 0.15 M NaCl and 500 μ L of plasma at 37° C. After 5 min, 100 μ L of 1 %, w/v CaCl₂ was added and the time to onset of fibrin registered.

The activity of antithrombin was studied in two ways: the first held in plasmas that were in direct contact with the magnetic support to evaluate the residual activity of antithrombin by automated chromogenic method. The second observed the activated partial thromboplastin time (aPTT Labtest Diagnóstica) in plasma by adding 20 μ L of eluate obtained with the gradient 1.0 M NaCl to the reaction system kit.

3. Results and discussion

3.1. Characterization of magnetic derivative

Conventional chemical synthesis of PANI has great advantage of producing a polymer of high molecular weight and high purity, which can be obtained in large amount in the form of a green powder [17]. In this work, the particles had an excellent magnetic activity by their conduct through a magnetic field. Moreover, these particles were properly coated with PANI, which was obtained through oxidation of aniline by ammonium persulfate (APS) and the reaction showed a "emerald" color (greenish), indicating the formation of polyaniline in its most stable form (Fig. 1) [18].




Fig 1: Magnetic matrix: (a) pure magnetite, (b) magnetite coated with PANI

3.2. Immobilization of heparin on magnetic matrix

Heparin chromatograph is a method of affinity chromatography used to purify or fractionate biological substances that can interact with heparin immobilized on insoluble support. The immobilization can occur by covalent bonding or physical adsorption [19]. Tab. 1 shows the amount of heparin (3 mg) recovered during the washing of the magnetic particles, those that are not immobilized to the support. With this, it can be seen that approximately

37% of the activated heparin was supplied covalently immobilized on supports coated with PANI. However, this is also heparin binding to particles even without PANI - around 15% - although at a lower rate, probably by nonspecific physical interactions. Further studies should be conducted to see if the pure magnetite is effectively capable of immobilizing heparin. Another important finding in the table is clear that the carboxylic groups of heparin, when activated with EDAC / NHS, are more reactive to promote a more efficient covalent interaction with the support coated with PANI. This is proved by observing a lower degree of immobilization to supports coated with PANI when heparin was not activated (22.7%). This shows that the polyaniline available chemical groups for the occurrence of covalent immobilization. These quantities of immobilized heparin are comparable to those described in the literature, disregarding the differences between the methods of restraint that were used [20, 21, 22].

mPANI-HEP mPANI-MAG-HEP MAG-HEP* HEP* Supernatant $1,91 \pm 0,70$ $2,60 \pm 0,21**$ $1,75 \pm 0,01$ $2,21 \pm 0,02$ 1st wash 0.11 ± 0.02 0.10 ± 0.02 0.53 ± 0.04 0.05 ± 0.03 2nd wash 0.04 ± 0.01 0.01 ± 0.01 0.11 ± 0.01 004 ± 0.01 3rd wash 0,00 0,00 0,00 0,00 Total $1,89 \pm 0,04$ $2,55 \pm 0,75$ $2,32 \pm 0.05$ $2,69 \pm 0,25$

Tab 1: Recovery of heparin (3mg) not fixed on magnetic particles

3.3. Separation/purification of plasma proteins

Heparin is not only an affinity ligand with biological specificity, but also an ion exchanger with high-charge density and distribution [23]. In this kind of chromatography, heparin covalently immobilized on matrix has two modes of interaction with proteins in sample solutions: a) acting as a specific affinity ligand, and b) serving as a cation exchanger through its high content of anionic sulphate groups. In 1973, Rosenberg and Damus suggested that heparin binds to antithrombin, causing a conformational change within antithrombin leading to a greatly accelerated reaction with thrombin and the formation of an inactive

^{*}Heparin has not previously treated with EDAC/NHS

^{**} Average ± SD

complex of the two proteins [24]. The interaction of heparin with antithrombin is a highly specific interaction. For any separation process could use ionic strength [25]. In the process of affinity purification of proteins from human plasma (Fig.2) using ionic strength (1.0 M NaCl), shows that the two forms of magnetite (just treated with heparin: MAG-HEP and that coated with polyaniline and immobilized heparin: mPANI-HEP) were able to purify a protein in fraction 45 when it was measured by 280 nm, while pure magnetite (MAG) does not serve to purify. However, adds to this other behavior that is the possibility of their own antithrombin or other proteins binding to the particles without treatment of any kind (pure magnetite), as shown in the same Fig. 2.





Fig.2: Affinity chromatography of human plasma protein using magnetic particle washed with phosphate buffer (PB) and increasing NaCl concentrations (0.25; 0.5; 1.0 M and 2.0 M).

3.4 Electrophoresis

Electrophoresis in polyacrylamide gel with sodium dodecyl sulfate was performed in an attempt to identify possible proteins adsorbed by different forms of magnetite. The electrophoresis (Fig.3A and 3B) shows protein with molecular weight 58 kDa (rectangle), corresponding to that referred to pure antithrombin with a greater amount of protein in fraction obtained from the preparation mPANI-HEP and MAG-HEP respectively. The main focus was antithrombin, because as you know, it specifically binds heparin with a Kd approximately 20 nM [26] and has many of its features fully described in the literature [27], which would facilitate the study. In Fig.3C there is a gel that no band was observed. Thus,

these experiments showed that protein adsorption occurs and that these were eluted with up to 1.0 M NaCl in the magnetic derivatives containing immobilized heparin, as shown in Fig. 2.






Fig. 3: *Electrophoresis.* The figures indicate the number of the fractions, according to the Fig. 2, collected by increasing NaCl concentrations (0,25; 0.5 and 1.0 M) from the plasma protein adsorbed onto the: a) mPANI-HEP; b) MAG-HEP and c) MAG. The rectangle shows the fractions that presented higher aPTT antithrombotic activity values. AT: Standard Antithrombin

^{*} Elutions performed in supports stored for 2 years.

3.5. In vitro anticoagulant assay

The aPTT test showed that the plasma that came into direct contact with the magnetic derivatives containing heparin activated or not with EDAC/NHS not coagulated, thus proving that heparin was indeed linked to support (Tab 2).

Tab 2: Activity anticoagulant / antithrombotic directlyon magnetic particles

Essay	Coagulation Time (min: s)
Plasma	00:50
MAG	01:31
MAG-HEP*	Not coagulated
MAG-HEP	Not coagulated
mPANI-HEP*	Not coagulated
mPANI-HEP	Not coagulated

^{*}heparin not previously treated with EDAC/NHS

To assess how much of antithrombin was retained in every form of magnetite, we measured the activity of plasma antithrombin remainder who underwent each type of magnetic support (Fig. 4). There is a decreased activity of antithrombin in plasmas that came into contact with the magnetite coated with PANI and heparin immobilized, although there has also been a rapid decline in support control without PANI and with immobilized heparin. Furthermore, the fraction 45 with purified antithrombin when incubated with the fresh plasma slows thromboplastin time by means of inhibition of thrombin as can be seen in eluates coming from the support containing heparin (Fig. 5). This is probably due to the support with heparin to retain other factors of blood coagulation [28]. Both Fig. (4 and 5) clearly demonstrate these antithrombotic activities are enhanced in support containing heparin, especially derivative which is coated with PANI.




Fig. 4: Activity of antithrombin present in fresh plasma and after direct contact with the support: a) Immediately synthesized (time zero) and b) 24 months stored at 4°C.




Fig. 5: Activated partial thromboplastin time (aPTT) of fresh plasma performed by adding small aliquot of the eluate (1.0 M) of derivatives magnetic: a) Immediately synthesized (time zero) and b) 2 years stored at 4°C.

4. Conclusion

It follows from the results that the magnetic particles coated with PANI and immobilized heparin (activated with EDAC/NHS) can be used to purification of proteins from human plasma, but to a lesser extent the pure particles and treated with heparin also can be used to the same purpose. Furthermore, both supports remained stable after 10 reuses although stored for 2 years.

5. Acknowledgements

The authors would like to thank CNPq for financial support and Mr. Adeilton Oliveira from the ANALAB clinical laboratory for his technical assistance.

6. References

- [1] D.Josic, F.Bal,; H.Schwinn. Isolation of plasma proteins from the clotting cascade by heparin affinity chromatography. Journal of Chromatography, 632,(1993)1.
- [2] T.Kuroiwa, Y Noguchi, M Nakajima, S Sato, S Mukataka, S Ichikawa. Productionof chitosan oligosaccharides using chitosanase immobilized on amylose-coated magnetic nanoparticles. Process Biochemistry 43(2008) 62.
- [3] G.Bayramoğlu, M.Y. Arıca. Preparation of poly(glycidylmethacrylate—methylmethacrylate) magnetic beads: Application in lipase immobilization. JournalofMolecular Catalysis B: Enzymatic 55(2008) 76.
- [4] L. M. Bruno, J.S. Coelho, E.H.M. Melo, J.L. Lima-Filho. Characterization of Mucormiehei lipase immobilized on polysiloxane-polyvinyl alcohol magnetic particles. WorldJournal of Microbiology and Biotechnology 21(2005) 189.
- [5] B.R.Pieters, G.Bardeletti. Enzyme immobilization on a low-cost magnetic support:kinetic studies on immobilized and co-immobilized glucose oxidase and glucoamylase. Enzyme and Microbial Technology 14(1992) 361.
- [6] R.Gangopadhyay, A. De, G.Ghosh, Polyaniline-poly(vinyl alcohol) conducting composite: material with easy processability and novel application potential. *Synthetic Metals* 123(2001) 2.
- [7] G. E.Asturias, A. G.Macdiarmid, R. P.Maccall, A. J. EPSTEIN, Theoxidation state of emeraldine base. Synthetic Metals 29(1989) E157.
- [8] J.Hong, P.Gong, D.Xu, L.Dong, S.Yao, , Stabilization of chymotrypsin by covalent immobilization on aminefunctionalized superparamagnetic nanogel. *Journal of Biotechnology*, , 128:3 (2007) 597.
- [9] B. Dong,B.L. He, C.L.Xu, H.L.Li, Preparation and electrochemical characterization of polyaniline/multi-walled carbon nanotubes composites for supercapacitor. Materials Science and Engineering: B 143:1-3(2007) 7.
- [10] A.Olad,R.Nabavi, Application of polyaniline for the reduction of toxic Cr(VI) in water. Journal of Hazardous Materials 147:3(2007) 845.

- [11] S. Singh, P.R Solanki, M.K. Pandey, B.D. Malhotra, Covalent immobilization of cholesterol esterase and cholesterol oxidase on polyaniline films for application to cholesterol biosensor. AnalyticaChimicaActa 568:1-2(2006) 126.
- [12] O. Ngamna, A. Morrin, S.E. Moulton, A.J.Killard, M.R.Smyth, G.G. Wallace, An HRP based biosensor using sulphonated polyaniline. Synthetic Metals 153:1-3 (2005)185.
- [13] K. F. Fernandes, C. S. Lima, H Pinho, C. H. Collins, Immobilization of Horseradish Peroxidase onto Polyaniline Polymers. *Process Biochemistry* 38:9(2003)1379.
- [14] A.M. A. C. Carneiro-Leão, E. A. Oliveira, L. B. Carvalho Jr., Immobilization of protein on ferromagnetic Dacron. Applied Biochemistry and Biotechnology, v. 33, (1991) 53.
- [15] G. B.Oliveira, L. B.Carvalho, Jr., M. P. C. Silva, Properties of carbodiimide treated heparin. Biomaterials, v. 24, (2003) 4777.
- [16] U. K. Laemmli, Cleavage of structural proteins during the assembly of head of bacteriophageT4. Nature, 227 (1970); 680.
- [17] S. K. Manoah; A. G. Macdiarmid; A. J. Epstein. The polyanilines: a novel class of conducting polymers, In: Conducting polymers emerging technologies, Technical Insights Inc: New Jersey, 1989; 27.
- [18]H. Goto;H. Yoneyama;F. Togashi;R. Ohta;A. Tsujimoto;E. Kita;K. Ohshima."PreparationofConductingPolymersbyEletrochemicalMethodsandDemonstrationofa PolymerBattery"JournalofChemical Education (2008), 1067.
- [19] G.Bickerstaff. Immobilization of enzymes and cells. In: Walker JM, editor. Methods in biotechnology 1. Totowa, NJ: Humana Press. (1997)
- [20]. L.Chen, C.Guo, Y. Guan, H. Liu,. Is of lactoferrin from acid whey by magnetic affinity separation. Separation and Purification Technology, 56(2007) 168.
- [21]. M.Björklund, & M. T. W. Hearn, Synthesis of silica based heparin affinity adsorbents. Journal of Chromatography A,728 (1996) 149.
- [22]. A Denizli, &E Piskin, Heparinimmobilized polyhydroxyethylmethacrylatemicrobeads for cholesterol removal: a preliminary report. Journal of Chromatography, 670(1995) 157.
- [23] A.Staby, M.B. Sand, R.G. Hansen, J.H. Jacobsen,., L.A Andersen, M.Gerstenberg, et al. Comparison of chromatographic ion-exchange resins IV. Strongand weak cationexchange resins and heparin resins. *J. Chromatogr. A* 1069,(2005) 65.
- [24] R. D. Rosenberg, P. S. Damus, J. Biol. Chem. 248(1973) 6490.
- [25] Bryson L. Gore, Anthony Harriman and Marie-Claude RichouxJournal of Photochemistry 19 (1982) 209.

- [26]. Capila, I. &Linhardt, R. J. Heparin Protein Interactions. Angewandte Chemie International Edition, 41 (2002) 390
- [27]. Biescas, H.; Gensana, M.; Fernandez, J.; Ristol, P.; Massot, M.; Watson, E.; Vericat, F. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained throught affinity chromatography. Haematologica, 83 (1998) 305.
- [28] Karlsson, G., Winge, S. Separation of latent, prelatent, and native forms of human antithrombin by heparin affinity high-performance liquid chromatography. Protein Expr. Purif. 33 (2004) 339.

7 Artigo a ser submetido à revista internacional "Composites Science and Technology



Título: Affinity separation of atithrombin using heparan sulfate immobilized on magnetic iron oxide particles coated with polyethylene terephthalate or polyaniline

Autores: Ricardo Souza Silva; Aurenice A. das Merces e Luiz B. Carvalho Jr.

Affinity separation of antithrombin using heparan sulfate immobilized on magnetic iron oxide particles coated with polyethylene terephthalate or polyaniline

Ricardo Souza Silva^a, Aurenice A. das Merces^a, Luiz B. Carvalho Jr. ^{a*}

^aLaboratório de ImunopatologiaKeizoAsami, Universidade Federal de Pernambuco, Cidade Universitária, 50670-901 Recife, PE, Brazil

* Corresponding Author:

Luiz Bezerra de Carvalho Júnior

Laboratório de Imunopatologia Keizo Asami (LIKA)

Departamento de Bioquímica, Universidade Federal de Pernambuco
Rua Professor Moraes Rego, 1235 Cidade Universitária, Recife - PE

CEP 50670-901

Telephone number: +55 81 2126.8484

Fax: +55 81 2126.8485

e-mail: lbcj@hotlink.com.br

Abstract

The present study aimed to develop magnetic matrices for the affinity separation of proteins using the heparan sulfate (HS) as a ligand. For this reason, ferromagnetic polyethylene terephthalate and magnetite coated with polyaniline were used for immobilization of HS. Initially, PET suffered hydrazinolysis and then was magnetized (mPET), and the magnetite (MAG) was synthesized and coated with PANI (mPANI). The HS was covalently fixed to the particles mPANI and mPET retaining 35 µg e 38.6 µg per mg of support respectively. Magnetic derivatives containing heparan sulfate immobilized (mPANI-HS and mPET-HS) were incubated with plasma and washed with NaCl gradients to release the fixed proteins and detect protein peaks at 280 nm. Electrophoresis of this eluate revealed bands corresponding to factors II, IIa, III, VII, XI, protein S and antithrombin, important proteins involved in the clotting process. Furthermore, activated partial thromboplastin time (aPTT) and prothrombin time (PT) of plasmas were prolonged when contacted with these eluates (1.5 and 2.0 M NaCl). The antithrombin activity in these eluates also demonstrated the effectiveness of the separation of this process using HS in both magnetic derivatives suggesting that these preparations are able to separate affinity components of human plasma as the factors of coagulation.

Keywords: antithrombin, heparansulfate; immobilization; polyaniline, polyethylene terephthalate.

1. Introduction

Glycoaminoglycans (GAGs) is widely used in biotechnology and one of its applications is in protein purification method using affinity chromatography [1 - 7]. This technique consists to fractionate or purify proteins and other biological substances through interaction (affinity) between molecules of interest fixed to the insoluble support [8]. The support used need to have a good profile as physical strength, insolubility, resistance to microbial attack as well as mechanical and thermal stability [9]. And when magnetized, facilitates the recovery of the carrier molecule to the immobilized affinity chromatographic processes, making this process easier and faster with the aid of a magnetic field.

Previous studies revealed that ferromagnetic particles PANI (polyaniline) or PET - Polyethylene terephthalate (polyester derived from the condensation of terephthalic acid with ethylene glycol), are useful to serve as supports and immobilize proteins [10, 11] or GAG [12]. In this study we investigated the use of heparan sulfate (HS) for the purpose of obtaining a magnetic matrix with this GAG covalently immobilized on solid supports ferromagnetic (PET and magnetite coated with PANI) with a view to the separation of plasma proteins.

The HS has group N-Glucosamine N-acetylated or N-sulfated. Several studies in the literature clearly show a high number biologically active proteins that can interact with heparan sulfate. The heparan, due to its great structural diversity, is able to interact with a variety of proteins: growth factors, chemokines, extracellular matrix components, DNA and RNA polymerases, coagulation factors, among others [13 - 17]. Thus, the focus of this paper was the separation of proteins that play an important homeostatic role in human plasma.

2. Material and methods

2.1. Materials

Films of Dacron (polyethyleneterephthalate) were donated by Terphane Ltda (Cabo de Santo Agostinho, PE, Brazil). The heparan sulfate was extracted from bovine lung [18] and was donated by the Clinical Laboratory (ANALAB) through the courtesy of Dr Adeilton Oliveira in partnership with Dr Leandro Fernandes Machado of UNB. Carbodiimide (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; EDAC), N-hydroxysuccinimide (NHS), hydrazine hydrate, ammonium persulfate (APS) and aniline (99%) were purchased from Sigma-Aldrich Ltda, whereas ferric and ferrous chlorides were from Merck SA. The kits of activated partial thromboplastin time (aPTT) and prothrombin time (PT) was acquired from Wiener Lab and Inlab Hemostasis respectively.

2.2 Synthesis of magnetite particles (MAG).

A magnetic matrix synthesis was conducted as follows: 25 ml of a solution of ferric chloride (1.1 M) and ferrous chloride (0.6 M) in a 2:1 ratio was combined with 125mL of water and adjusted to pH solution to 11 with ammonium hydroxide. Then the mixture was heated in a water bath at 100°C under vigorous stirring for 30 min. The black precipitate obtained, which are magnetite particles (MAG), washed thoroughly with distilled water to remove excess ammonia and to achieve a neutral pH. The material was then filtered and oven dried, screened and homogenized in sieve opening 250µm.

2.3. Coating the magnetic matrix with polyaniline.

The magnetic particles (<250µm) were treated with ammonium persulfate 0.61 M (APS; Sigma) prepared in 2.0 M HCl, which was under gentle shaking for 30 minutes at 25°C and after successive washes with 10 mM PBS pH 7.2 were made. The support treated with ammonium persulfate (APS) was subsequently incubated with 1.0 ml 0.44 M aniline (Sigma; 99%) for 60 minutes at 4°C to obtain coated magnetite support polyaniline (mPANI).

2.4. Hydrazinolysis of PET

The hydrazinolysis of the PET was conducted as follows: 10 g of PET (sheets) were added to a 250 ml erlenmeyer flask, and this material was added 100 ml of methanol and 25 mL of hydrazine hydrate. This mixture was subjected to agitation at 150 rpm at 40 ° C for 24 hours [19]. After this process, we obtained a whitish liquid filtrate which was then dried and sieved in sieve opening 250µm. The final product is obtained is a fine white powder (PET-hydrazide) that will be used later in step magnetization.

2.5. Magnetization of PET

The magnetization was conducted by preparing a suspension according to the following proportions: 2g PET-hydrazide in water, followed by addition of 10 ml of a solution of ferric and ferrous chlorides in a 1:1 ratio, the pH was raised to 11 by adding ammonium hydroxide, and finally, this mixture was kept under vigorous stirring at 100°C. Finally, the black precipitate was obtained which was washed thoroughly with water to remove excess ammonium hydroxide, reaching a neutral pH. Shortly afterwards the material was filtered and dried at 50°C, then homogenized and sieved in sieve opening 250µm. The particles of ferromagnetic PET (mPET) were then synthesized.

2.6. Immobilization of heparan sulfate (HS) covalently on magnetic support: mPET and mPANI.

For activation of heparan sulfate (1 ml containing 3mg/mL) was used in an amount carbodiimide (EDAC) in proportion to the Heparan 1:1 w/w and an amount of sulfate N-hydroxysuccinimide (NHS) in proportion of EDAC 1:1 M/M. The resulting solution was subjected to 1 hour of agitation at a pH of around 4.5 to 4.8 at 25°C. At the end of the reaction, the pH was raised to 8 with NaOH. The activated heparin solution was incubated for 72 hours at room temperature with 30 mg of supports magnetic particles coated with PANI

(mPANI) and magnetic PET (mPET) obtaining the magnetic derivatives: mPANI-HS and mPET-HS.

2.7. Heparan sulfate determination

To determine the amount of heparan sulfate that was immobilized to the supports was necessary to make a standard curve for measurement of heparan sulfate with the use of methylene blue dye [20]. After the incubation period, the samples were withdrawn from the supernatant and of washed 1 and 2. The dye methylene blue (0.005% 0.01% NaCl 0.2 N) was used to determine the amount of heparan sulfate which was contained in supernatant, wash 1 and Wash 2, this measurement was made in the spectrophotometer wavelength of 664 nm and yield immobilization was calculated as the difference between the quantity supplied and that found in supernatants and washed.

2.8. Separation of plasma protein

In each of 30 mg of matrix containing heparan sulfate, add 1 ml of citrated human plasma. This mixture was stirred for 45 minutes at room temperature. Then, with the aid of a magnetic field of 6000 Oe, supernatants were collected and washings performed with phosphate buffer pH 7.2 to obtain low concentrations of protein in the eluate (λ = 280 nm). Subsequently, the matrix was eluted with the same buffer containing increasing concentrations of 0.5 M, 1.0 M, 1.5 M and 2.0 M sodium chloride. The process of incubation and elution were repeated about five times, to increase the total protein mass, dialyzed, lyophilized and finally, analyzed on electrophoresis SDS/PAGE gel to 10.0% and stained with silver nitrate.

2.9. Prothrombin time (PT), activated partial thromboplastin time (aPTT) and antithrombin activity.

The quantitative determination of antithrombin activity in the fractions was established using a chromogenic (SAR-PRO-ARG p-Nitroanilide) assay (TriniCHROMTM Antithrombin IIa, Trinity Biotech, Ireland). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were made with the eluates (fractions) obtained from the increasing concentrations of NaCl. An aliquot of 20 μ L was added to the reaction system kit according to the standards required by manufacturer instructions.

3. Results and discussion

3.1. Synthesis of magnetic particles: magnetite (MAG), magnetite coated with PANI (mPANI), and ferromagnetic PET (mPET)

The particles had an excellent magnetic activity by their conduct facing a magnetic field of 6000 Oe. Magnetite (Fe3O4) was indeed obtained by co-precipitation of ferric ions (Fe³⁺) and ferrous (Fe²⁺). The magnetic particles were actually coated with polyaniline. This can be seen by the reaction showed a color between green and blue being indicative of polyaniline in its most stable form – state esmeraldine. Although a small portion of the material was lost during the washes, mPET support also obtained excellent magnetic activity.

3.2. Hydrazinolysis reaction

The PET had hydrazinolysis total time of 24 h. Therefore, this was the time needed to react all of Dacron sheets (10g) with hydrazine hydrate. Thus, the hydrazide chemical groups that are important for the covalent immobilization of heparan sulfate were added.

3.3. Immobilization of heparan sulfate on magnetic derivatives: mPET and mPANI

Table 1 shows the amount of heparan sulfate (3mg) recovered during the washing of the magnetic particles, in other words, those that are not immobilized to the support. With this, it can be seen that the amount of heparan sulfate (HS) immobilized was 35μg/mg on mPANI support (mPANI-HS). However, there is also heparan sulfate binding (18μg/mg), although at a lower rate, on pure magnetite (MAG). The table also shows that 38.6 μg of HS was immobilized in each mg of ferromagnetic PET (mPET). This is explained due to the

covalent interaction between the hydrazide groups present in support mPET forming a specific amide bond with the most reactive carboxyl groups of heparan sulfate because of its activation by EDAC and NHS.

Table 1: Recovery heparan sulfate (3mg) not fixed tomagnetic support mPANI and mPET

	mPANI-HS	MAG (Control)	mPET-HS	
Supernatant	$1,69 \pm 0,23$	$2,31 \pm 0,31$	$1,52 \pm 0,44*$	
1 st wash	$0,19 \pm 0,09$	0.12 ± 0.03	$0,23 \pm 0,02$	
2 nd wash	0.07 ± 0.04	0.03 ± 0.07	0.09 ± 0.02	
3 rd wash	0,00	0,00	0,00	
Total	$1,95 \pm 0,36$	$2,46 \pm 0,41$	$1,84 \pm 0,48$	

^{*} Average ± SD

3.4. Separation of plasmaprotein.

Affinity chromatography is recognized as a simple and effective method for separating various molecules contained in a mixture using for this physicochemical property of the distribution from the components of the mixture into two phases, one stationary and the other movable, which are in intimate contact. The specificity between the elements of these phases allows you to remove the mobile component of the mixture. In this work, the stationary phase is represented by the supports mPANI and mPET containing immobilized heparan (mPANI-HS and mPET-HS respectively).

Fig. 1 and 2 show the leaching of plasma proteins attached to the stationary phases (mPANI-HS and mPET-HS respectively). First, it is observed that the absorbance at 280 nm is indicative of the presence of protein in the laundered. Before elution process repeated, washing with phosphate buffer pH 7.2 were performed. When increasing the added solutions of 0.5 M, 1.0 M, 1.5 M and 2.0 M NaCl in the same buffer (shown in the figures) protein peaks were eluted in each fraction are observed. It is noted that this behavior was observed in

eluates of plasma proteins employing the two magnetic support which have the covalently immobilized heparan sulfate: mPANI-HS and mPET-HS. The fractions corresponding to each peak were subjected to electrophoresis. These eluted proteins are, among others, mainly serine proteases of coagulation cascade, contain large numbers of the basic amino acids (lysine, arginine and in some cases histidine). These basic residues can be found in linear arrangements or in spatial folded clusters. Nevertheless, links can also involve basic amino acids which are distant in the linear sequence of the protein are pooled and protein in the folded state [21 - 25]. However, they can be separated from the solid phase by ionic strength as shown in Fig. 1 and Fig. 2.




Figure 1: Affinity chromatography of human plasma proteins using magnetite coated with polyaniline and heparan immobilized: mPANI-HS was incubated with human plasma and washed with phosphate buffer ph 7.2, to balance the absorbance (280 nm) – 20th fraction: the particles were then washed with buffer containing increasing concentrations of NaCl (0.5M; 1.0M; 1.5M and 2.0M).




Figure 2: Affinity chromatography of human plasma proteins using ferromagnetic PET with heparan sulfate immobilized: mPET-HS was incubated with human plasma and washed with phosphate buffer ph 7.2, to balance the absorbance $(280 \text{ nm}) - 20^{\text{th}}$ fraction: the particles were then washed with buffer containing increasing concentrations of NaCl (0.5M; 1.0M; 1.5M and 2.0M).

3.5. Influence of the eluates on coagulation tests

Table 2a and 2b shows the prothrombin time (PT), activated partial thromboplastin time (aPTT) and antithrombotic activity, clinical test commonly used to diagnosing the absence of coagulation factors. Proteins presenting and increasing the aPTT and PT were collected from the mPANI-HS and mPET-HS that are equivalents to NaCl concentrations of 1.5 and 2.0 M, this is due to the fact these proteins have been held in the magnetic derivatives. The proteins eluted with lower NaCl concentrations did not present antithrombotic activity and relevant aPTT and PT values. This finding is a strong indication of the effectiveness of magnetic supports (mPANI-HS and mPET-HS) in the separation of antithrombin and other coagulation factors, since it is known that there is an intense physiological interaction between this glycoprotein with heparin, which has structural similarity with heparan sulfate [26].

Table 2 – The activated partial thromboplastin time (aPTT), prothrombin time (PT) and antithrombin activity of the fractions collected from the elution of the plasma proteins adsorbed onto the: a) mPANI-HS and b) mPET-HS.

a)						b)					
	Fractions	[NaCl]	aPTT1	PT ²	AT activity		Fractions	[NaCl]	aPTT1	PT ²	AT activity
	(Number)	(M)	(min: s)	(min: s)	(%)		(Number)	(M)	(min: s)	(min: s)	(%)
	20	PB	00:38	00:13	0		20	PB	00:36	00:12	0
	25	0.5	00:40	00:12	0		25	0.5	00:38	00:11	0
	30	0.5	00:39	00:12	0		30	0.5	00:37	00:12	0
	35	1.0	00:44	00:15	0		35	1.0	00:43	00:14	0
	40	1.0	00:40	00:14	0		40	1.0	00:39	00:12	0
	45	1.5	02:41	00:39	3.11		45	1.5	02:36	00:36	2.97
	48	1.5	02:23	00:30	2.27		50	1.5	02:18	00:27	2.12
	50	2.0	01:21	00:35	2.44		55	2.0	01:27	00:31	1.97
	55	2.0	01:03	00:27	0.20		60	2.0	01:11	00:20	0.23

¹Reference values: 30 – 42 seconds; ² Reference values: 12 – 15 seconds. PB: 10 mM phosphate buffer, pH 7.2.

3.6. Electrophoresis

The findings presented in Table 2 were corroborated with the electrophoresis results (Fig. 3). Suggestive bands of protein significant in the coagulation cascade can be visualized for the elutions with 1.5 and 2.0 M NaCl that revealed higher aPTT and antithrombotic activity values: a) factor XI (160 kDa); b) protein S (75 kDa); c) factor II (72kDa); d) antithrombin (58 kDa), e) factor VII (55 kDa); f) factor III (37 kDa) and g) factor IIa (36,7 kDa) [27,28]. These are molecules which can interact physiologically with the heparan sulfate and depends on the overall organization of the glycosaminoglycan chain rather than on the fine structure of the individual sequences to achieve its functional role [29-32]. This result are clearly shown in both support containing heparan sulfate covalently immobilized: mPANI-HS (Fig. 3A) and mPET-HS (Fig. 3B).




Figure 3: SDS-PAGE of the Fractions collected from the plasma protein adsorbed onto: A) mPANI-HS and B) mPET-HS. Elutions were carried out using phosphate buffer (PB) and increasing NaCl concentrations (0.5; 1.0; 1.5 and 2.0 M). The figures indicate the number of the fractions (f) collected according to the Fig.1 and Fig.2. Bands: a) factor XI; b) protein S; c) factor II; d) AT: antithrombin; e) factor VII; f) factor IIIand g) factor IIa.

4. Conclusion

The data presented confirm the presence of heparan sulfate bound covalently to magnetic derivatives mPANI and mPET. Therefore, these magnetic derivatives can be a useful tool in purification / separation not only of antithrombin process, but also of other proteins of interest to study the coagulation cascade.

Acknowledgements

The authors wish to acknowledge financial support from the Brazilian agency CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico). The authors also wish to thank the courtesy of Prof Dr Leandro Fernandes Machado of UNB (Universidade de Brasília

- Brazil) and the biomedical Mr Adeilton Oliveira to provide heparan sulfate and give space for the development of some experiments respectively.

References

- [1] Thorslund, S; Sanchez, J; Larsson, R; Nikolajeff, F; Bergquist, J. Bioactive heparin immobilized onto microfluidic channels in poly(dimethylsiloxane) results in hydrophilic surface properties. Colloids and Surfaces. B, Biointerfaces 2005; v. 46, n. 4, p. 106–113.
- [2] Heyligers, J. M. M; Verhagen, H. J. M; Rotmans, J. I; Weeterings C; Groot, P. G. D; Moll, F. L; Lisman T. Heparin immobilization reduces thrombogenicity of small-caliber expanded polytetrafluoroethylene grafts. Journal of vascular surgery 2006; v. 43, n. 3, p. 587-591.
- [3] Kondo, S; Fukunaga, Y; Oikawa, M; Sasai, Y; Kuzuya, M. Plasma-Assisted Immobilization of Heparin onto Low-Density Polyethylene Surface. Chemical & Pharmaceutical Bulletin 2008; .v.56, n. 7, p. 921-925.
- [4] Huh J. B; Lee J. Y; Lee K. L; Kim S. E; Yun M. J; Shim J. S; Shim J.S.; Shin S.W. Effects of the immobilization of heparin and rhPDGF-BB to titanium surfaces for the enhancement of osteoblastic functions and anti-inflammation. The Journal of Advanced Prosthodontics 2011; v. 3, n. 3, p. 152-160.
- [5] Chandy T; Das G. S; Wilson R. F; Roa G. H. R. Use the plasmaglow for surface-engineering biomolecules to enhance blood compatibility of Dacron and PTFE vascular prosthesis. Biomaterials 2000; v. 21, n. 7, p. 699-712.
- [6] Murugesan, S; Xie, J; Linhardt, R.J. Immobilization of heparin: approaches and applications. Current Topics in Medicinal Chemistry 2008; 90-100.
- [7] Xing Z. C.; Chang Y.; Kang I. K. Immobilization of biomolecules on the surface of inorganic nanoparticles for biomedical applications, Science and technology Advanced Materials 2010; v. 11, n. 1, p. 1-17.
- [8] Xiong, S; Zhang, L; He, Q.Y. Fractionation of Proteins by Heparin Chromatography; 2D PAGE: Sample Preparation and Fractionation. Methods in Molecular Biology™ 2008; 424, 213–221.
- [9] Caramori, S. S; Fernandes, K. F. Covalent immobilization of horseradish peroxidase onto poly(ethylene terephtalate)-poly(aniline) composite. Process Biochemistry 2004; v. 39, p. 883-888.

- [10] Barbosa, E. F; Molina F. J.; Lopes, F. M; Garcia-Ruiz, P. A; Caramori, S. S; Fernandes, K. F. Immobilization of Peroxidase onto Magnetite Modified Polyaniline. The Scientific World Journal 2012; v. 2012, p. 01-05.
- [11] Caramori, S. S; Faria F. N; Viana, M. P; Fernandes, K. F; Carvalho, L. B. Trypsin immobilization on discs of polyvinyl alcohol glutaraldehyde/polyaniline composite. Materials Science and Engineering C 2011; v. 31, p. 252–257.
- [12] Josic, D; Bal, F and Schwinn, H. Isolation of plasma proteins from the clotting cascade by heparin affinity chromatography. Journal of Chromatography 1993; 632, 1.
- [13] Sasisekharan, R; Shriver, Z; Venkataraman, G; Narayanasami, U. Roles of heparansulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002; 2: 521–528.
- [14] Aviezer, D and Yayon, A. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. ProcNatlAcadSci USA 1994; 91: 12173–12177.
- [15] Koopmann, W; Ediriwickrema C and Krangel, MS. Structure and function of the glycosaminoglycan binding site of chemokine macrophage inflammatory protein-1 beta. J Immunol 1999; 163: 2120–2127.
- [16] Furukama, K. and Bhavanandan, V.P. Influences of anionic polysaccharides on DNA synthesis in isolated nuclei and by DNA polymerase alpha: correlation of observed effects with properties of the polysaccharides. BiochimBiophysActa 1983; 740: 466–475.
- [17] Dreyfuss, J. L; Regatieri, C. V; Jarrouge; T. R; Cavalheiro, R. P; Sampaio, L. O; Nader, H. B; Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. Anais da Academia Brasileira de Ciências 2009; 81(3): 409-429.
- [18] Nader, H. B; Pinhal, M. A. S; Baú, E. C; Castro, R. A. B; Medeiros, G. F; Chavante, S. F; Leite, E. L; Trindade, E. S; Shinjo, S. K; Rocha, H. A. O; Tersariol, I. L. S; Mendes, A; Dietrich, C. P. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells. Brazilian Journal of Medical and Biological Research 2001; v. 34, p. 699-709.
- [19] Carneiro-Leão, A.M. A. C.; Oliveira, E. A.; Carvalho Jr., L. B. Immobilization of protein on ferromagnetic Dacron. Applied Biochemistry and Biotechnology, v. 33, p. 53-58, 1991. Carneiro-Leão, A.M. A. C.; Oliveira, E. A.; Carvalho Jr., L. B. Immobilization of protein on ferromagnetic Dacron. Applied Biochemistry and Biotechnology 1991; v. 33, p. 53-58.

- [20] Oliveira, G. B; Carvalho, Jr. L. B; Silva, M. P. C. Properties of carbodiimide treated heparin. Biomaterials 2003; v. 24, p. 4777-4783.
- [21] Capila I and Linhardt RJ.Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391–412.
- [22] Hileman Re, Fromm Jr, Weiler Jm and Linhardt RJ. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 1998; 20: 156–167.
- [23] Krilleke D, Deerkenez A, Schubert W, Giri I, Robinson Gs, Ng Ys And Shima Dt. Molecular mapping and functional characterization of the VEGF- 164 heparin-binding domain. J Biol Chem 2007; 282: 28045–28056.
- [24] Mulloy B And Linhardt RJ. Order out of complexity- protein structures that interact with heparin. Curr Opin Struct Biol 2001; 11: 623–628.
- [25] Vives Rr, Crublet E, Andrieu Jp, Gagnon J, Roussellep And Lortat-Jacob H. A novel strategy for defining critical amino acid residues involved in protein/ glycosaminoglycan interactions. J Biol Chem 2004; 279: 54327–54333.
- [26] Casu B, Choay J, Ferro Dr, Gatti G, Jacquinet Jc, Petitou M, Provasoli A, Ragazzi M, Sinay P And Torri G. Controversial glycosaminoglycan conformations. Nature 1986; 322: 215–216.
- [27] Buchta, C., Dettke, M., Funovics, P. T., Hocker, P., Knobi, P., Macher, M., Quehenberguer, P., Treitl, C., Worel, N. Fibrin Sealant Produced By The Cryoseal®Fs System: Product Chemistry, Material Properties And Possible Preparation In The Autologous Preoperative Setting. Vox Sanguinis 2004 V.86, P.257-262.
- [28] FRANCO R. F. Fisiologia da coagulação, anticoagulação e fibrinólise. Medicina, Ribeirão Preto 2001; v.34, p.229-237, jul./dez.
- [29] Gambarini Ag, Miyamoto Ca, Lima Ga, Nader Hb And Dietrich Cp. Mitogenic activity of acidic fibroblast growth factor is enhanced by highly sulfated oligosaccharides derived from heparin and heparan sulfate. Mol Cell Biochem 1993; 124: 121–129.
- [30] Kreuger J, Spillmann D, Li Jp And Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 2006; 174: 323–327.
- [31] Sampaio L, Tersariol I, Lopes C, Bouças R, Nascimento F, Rocha H And Nader H. Heparins and heparans sulfates. Structure, distribution and protein interactions. In: Verli H (Ed), Insights Into Carbohydrate Structure And Biological Function. Transworld Research Network, Kerala, 2006; p. 1–24.

[32] Suarez Er, Nohara As, Mataveli Fd, de Matos Ll, Nader Hb And Pinhal M.A. Glycosaminoglycan synthesis and shedding induced by growth factors are cell and compound specific. Growth Factors 2007; 25: 50–59.

8 Conclusões

- As partículas magnéticas sintetizadas se mostraram adequadas quando submetidas a um campo magnético de 6000 Oe, facilitando seu manuseio em métodos de separação por afinidade.
- A heparina foi imobilizada com sucesso aos suportes magnéticos de PET, bem como à magnetita revestida com polianilina. Em um menor percentual, a heparina também ficou retida à magnetita sem o revestimento com PANI. Sendo assim, o revestimendo das partículas magnéticas com a polianilina (PANI) foram importantes para a efetivação do processo de imobilização covalente da heparina, podendo esta ser ativada ou não com EDAC/NHS. Porém, a heparina funcionalizada com EDAC/NHS imobilizada na matriz magnética revestida com PANI, apresentou uma atividade melhor no processo de fracionamento do plasma, onde houve uma maior ligação das proteínas a heparina presente neste suporte.
- Todas as matrizes magnéticas com heparina imobilizada se demonstraram estáveis em seu uso mesmo após 2 anos estocadas a 4 °C. A estabilidade também foi mantida após 10 ciclos consecutivos de reutilização no processo de separação por afinidade da antitrombina. Assim sendo, esses derivados tendem a ser uma alternativa interessante quanto ao apelo industrial.
- O dobro de quantidade do heparan sulfato foi covalentemente fixado às partículas de magnetita revestidas com PANI e também no PET magnetizado se comparado à matriz controle. Isso demonstrou que também é possível imobilizar o heparan sulfato quando devidamente funcionalizado com EDAC/NHS.
- As eletroforeses mostraram claramente a purificação da antitrombina em todos os suportes sintetizados. Este resultado foi corroborado com o teste amidolítico que avaliou a presença da antitrombina nos eluatos bem como sua atividade no retardo no tempo de coagulação plasmático.
- Os derivados contendo heparan sulfato, além da antitrombina, podem separar importantes proteínas da coagulação. Isso foi comprovado mediante os testes de TTPa e TP, os quais avaliam a via intrínsceca e extrínseca da coagulação das quais essas proteínas fazem parte.

- Os derivados magnéticos assim obtidos prestam-se à purificação de proteínas do plasma humano, especialmente a antitrombina, através da técnica de adsorção por afinidade à heparina e ao heparan sulfato.

9 Anexos

9.1 Instruções para Autores



BIOMATERIALS IF: 8.496

The peer review submission system for Biomaterials is located here: http://ees.elsevier.com/biomat/

The Elsevier Editorial System (EES) is a web-based submission and review system. Authors may submit manuscripts and track their progress through the system to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.

Please register at: http://ees.elsevier.com/biomat/

Referees, whose names are not normally disclosed to the authors, will study all contributions which the Editor-in-Chief deems to be of sufficient significance and interest to be sent for peer review. The criteria by which this initial assessment is made include relevance to the scope of the journal, the originality of the work and its significance to the broad development of the field of biomaterials.

Before You Begin

All authors, especially those submitting to the journal for the first time, are encouraged to read the following document authored by the Editor in Chief, which gives an overview of the journal as well as the writing and selection process of academic publishing as it relates to Biomaterials: Writing Papers for Biomaterials.

Ethics in Publishing: For information on Ethics in Publishing and Ethical guidelines for journal publication see http://www.elsevier.com/authorethics and http://www.elsevier.com/ethicalguidelines.

Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts: Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding

author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Mandatory Author Declaration: In addition to uploading manuscripts and figures, it is required that the corresponding author of each manuscript uploads a separate Author Declaration. All authors must sign this declaration; the corresponding author may not sign on behalf of other authors.

This Declaration covers a number of logistic and ethical issues. Please use the template given above for this Declaration. Authors may save this template, obtain the required signatures and then upload it as an integral part of their submission. The editorial process will not begin until and unless all authors have signed the declaration.

N.B.: The Author Declaration is independent of, and in addition to, the "Journal Publishing Agreement" agreement which is issued on acceptance.

Amendments to Manuscripts

In order to maintain the integrity of the scientific record, the version that is published in an issue on ScienceDirect and in print MUST be identical. One set of page proofs will be sent to the corresponding author. Please note that authors are urged to check their proofs carefully before return, but corrections are restricted to typesetting errors only. Proofs are NOT to be considered as drafts. No changes in, or additions to, the accepted (and subsequently edited) manuscript will be allowed at this stage. Proofreading is solely the responsibility of the corresponding author.

Copyright

All authors must sign the "Journal Publishing Agreement" before the article can be published. An e-mail (or letter) will be sent to the corresponding author confirming receipt of the manuscript together with an agreement form or a link to the online version of this agreement. This transfer agreement enables Elsevier Ltd to protect the copyrighted material for the authors, but does not relinquish the author's proprietary rights. As an author you (or your employer or institution) retain certain rights; for details you are referred to: http://www.elsevier.com/authorsrights.

The copyright transfer covers the exclusive rights to reproduce and distribute the article. Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult http://www.elsevier.com/permissions.

Role of the Funding Source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report;

and in the decision to submit the paper for publication. If the funding source(s) had no such involvement then this should be stated. Please see http://www.elsevier.com/funding.

Funding Bodies Agreements and Policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

Open Access

This journal offers authors two choices to publish their research;

- 1. Open Access
- Articles are freely available to both subscribers and the wider public with permitted reuse
- An Open Access publication fee is payable by authors or their research funder

2. Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)
- No Open Access publication fee

All articles published Open Access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

Creative Commons Attribution (CC-BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Creative Commons Attribution-Non Commercial-ShareAlike (CC BY-NC-SA): for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY NC SA).

Creative Commons Attribution-NonCommercial-NoDerivs (CC-BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published Open Access.

The Open Access publication fee for this journal is \$USD 3300, excluding taxes.

Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing

Manuscript Preparation

General: Manuscripts must be word processed (preferably in Word format), double-spaced with wide margins and a font size of 12 or 10 pt. Files prepared in LaTEX are not supported.

Figure captions should be in Arial font 9pt. Please check the current style of the journal, particularly the reference style (Vancouver), and avoid excessive layout styling as most formatting codes will be removed or replaced during the processing of your article. In addition, do not use options such as automatic word breaking, justified layout, double columns or automatic paragraph numbering (especially for numbered references). However do use bold face, italic, subscripts, superscripts etc. The corresponding author should be identified (include a Fax number and E-mail address). Full postal addresses must be given for all co-authors. The Editors reserve the right to adjust style to certain standards of uniformity. The preferred style is: Surname, Initials, Department, Institution, City/State, Postal Code, Country. Authors should retain copies of all versions of their manuscript submitted to the journal. Authors are especially requested to be vigilant over the submission of the correct version of the manuscript at the various stages of the editorial process.

English Language: Manuscripts should be proof-read and have English language errors corrected before submission as we may have to return papers due to poor language usage. Authors who require information about language editing and copyediting services pre- and post-submission please visit http://www.elsevier.com/languagepolishing for more information.

Paper Length: Authors are urged to write as concisely as possible.

Abstracts: All manuscripts are to be supplied with an Abstract of about 100-200 words in length.

Keywords: Authors must provide 4-6 keywords for indexing purposes. A keyword list can be found at the end of these instructions. click here).

Text: Follow this order when typing manuscripts:Title, Authors, Affiliations, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusions, Acknowledgements, References, Appendix (where necessary), Figures, Figure Captions and Tables, Supplementary Data. The corresponding author should be identified with an asterisk and footnote. All other footnotes (except for table footnotes) should be identified with superscript Arabic numbers. An abbreviated title for use as a running headline should also be supplied. Authors are requested to acknowledge funding sources for the work.

Units: The SI system should be used for all scientific and laboratory data; if, in certain instances, it is necessary to quote other units, these should be added in parentheses. Temperatures should be given in degrees Celsius. The unit 'billion' (109 in America, 1012 in Europe) is ambiguous and must not be used. If a large number of symbols are used it is helpful if authors submit a list of these symbols and their meanings.

References: All publications cited in the text should be presented in a list of references following the text of the manuscript. In the text refer to references by a number in square brackets on the line (e.g. Since Peterson[1]), and the full reference should be formatted according to the permutation of the Vancouver reference system with numbers in the text. It is suggested that authors refer to the following link for a comprehensive overview of the Vancouver reference styles: Vancouver Reference Styles

Examples of formatting follow:

1. Driessens FCM, Boltong MG, Bermudez O, Planell JA. Formulation and setting times of some calcium orthophosphate cements: a pilot study. J Mater Sci: Mater Med 1993;4:503-508.

- 2. Nancollas H. In vitro studies of calcium phosphate crystallisation. In: Mann S, Webb J, Williams RJP, editors. Biomineralization. Chemical and biochemical perspectives. New York: VCH, 1989. p. 157-182.
- 3. Brown W, Chow LC. Combinations of sparingly soluble calcium phosphates in slurries and paste as mineralizers and cements. US Patent No. 4612053, 1986.

N.B.: "Et al" must be used after the first 6 authors have been named. Biomaterials does not use the publication month or day.

Online Sources: References to online sources, including articles in press, should contain at a minimum the full URL and year the source was accessed. Furthermore, if known, the following information should be given: author names, dates, reference to a source publication. Examples of formatting follow:

- 1. UK House of Commons Science and Technology Committee. Scientific Publications: Free for All? Tenth Report of Session 2003-4 Volume 1. London: The Stationary Office Ltd. Online. 2004 July. Available from URL: http://www.publications.parliament.uk/pa/cm200304/cmselect/cmsctech/399/39902.html
- 2. Wellcome Trust. Economic Analysis of Scientific Research Publishing. Histon, UK: Wellcome Trust. Online. 2003. Available from URL: http://www.wellcome.ac.uk/doc_wtd003181.html
- 3. Keeney M, Lai JH, Yang F. Recent progress in cartilage tissue engineering. Curr Opin Biotechnol. 2011. Available from URL: http://www.ncbi.nlm.nih.gov/pubmed/21531126 (DOI: 10.1016/j.copbio.2011.04.003).

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Save text in illustrations as "graphics" or enclose the font.
- Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Produce images near to the desired size of the printed version.
- Submit each figure as a separate file.

A detailed guide on electronic artwork is available on our website: http://www.elsevier.com/artworkinstructions

You are urged to visit this site; some excerpts from the detailed information are given here. Formats

Regardless of the application used, when your electronic artwork is finalised, please "save as" or convert the images to one of the following formats (note the resolution requirements for drawings, line halftones. and line/halftone combinations given below): drawings. Embed the font or save the text as "graphics". TIFF: color or grayscale photographs (halftones): always use a minimum of 300 dpi. Bitmapped line drawings: of TIFF: use minimum 1000 TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is

DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications please supply "as is".

Please do not:

- Supply embedded graphics in your wordprocessor (spreadsheet, presentation) document;
- Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is too low;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color in print or on the Web only. For further information on the preparation of electronic artwork, http://www.elsevier.com/artworkinstructions. Please note: Because of technical complications which can arise by converting color figures to "gray scale" (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

Video Data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a maximum size of 30 MB and running time of 5 minutes. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content. Files can be stored on diskette, ZIP-disk or CD (either MS-DOS or Macintosh). Audio Slides: The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

After Acceptance

Proofs: One set of page proofs in PDF format will be sent by e-mail to the corresponding author and should be returned within 48 hours of receipt. The average amount of time

between acceptance and receipt of typeset proof is 6 working days. Papers are published in print within another 8 weeks upon receipt of author corrections. Corrections should be restricted to typesetting errors. Any queries should be answered in full. Please note that authors are urged to check their proofs carefully before return.

Elsevier now sends PDF proofs which can be annotated; for this you will need to download Adobe Reader© version (or higher) available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win. If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Track a Paper: Authors can track their paper status online after the paper has been accepted and forwarded to the Publisher. Enter your Elsevier reference number (JBMT xxx) and the Corresponding author's the following web family name at page: http://www.elsevier.com/trackarticle. Corresponding authors will receive an acknowledgement email from Elsevier with the reference number and the family name on it. Authors can also go to the 'track a paper' page by clicking onto the 'track a paper' button on the left hand side of the journal home page.

Offprints: The corresponding author will be provided with a PDF of the article via email. The PDF is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms of use. Additional paper offprints can be ordered by the authors. An order form with prices will be sent to the corresponding author.

Author Enquiries: For enquiries relating to the submission of articles (including electronic submission where available) please visit this journal's homepage. You can track accepted articles at http://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.



REACTIVE AND FUNCTIONAL POLYMERS IF: 2.653

DESCRIPTION

The Journal publishes papers dealing with new ideas and developments in the science and technology of polymers with functional groups that provide specific chemical reactivity or physico-chemical behaviour. The scope covers organic and inorganic functional polymers, acting as reagents, catalysts, carriers of protecting groups, templates, ion-exchangers, selective sorbents, chelating agents, supports for enzymes and cells, and the like. It also includes reactive cross-linkable prepolymers, degradable or bioactive polymers, polymer resists, conducting polymers, and film-forming polymers.

Contributions have to present thorough molecular and material characterisation data, and may deal with the synthesis of the above polymers or with their applications in organic synthesis, catalysis, water or effluent treatment, separations, recovery, lithography, microelectronics, information storage, energy conversion, diagnostics, drug delivery, coating and encapsulation, and adhesion.

The Journal addresses two main audiences: those engaged in the synthesis of new materials and the development of novel techniques, and those concerned with technology and practical applications in the laboratory or plant. The Journal encourages, and serves as a forum for, the dialogue between these two groups.

Papers on a broad spectrum of topics are encouraged. Emphasis is on work at the frontiers of science or technology and furthering the interaction between researcher and practical engineer, rather than on details of theory or application. Full-length papers and review articles will be considered. However, authors intending to write a review should contact an Editor first. Uninvited reviews will not be considered. All material submitted must be original, that is it may not have been submitted elsewhere for publication. Lack of originality, insufficient molecular characterisation, poor comparison with the current state of literature and with the authors' own production are, individually, sufficient reasons for rejection.

AUDIENCE

Chemists, Chemical Engineers, Pharmaceutical Chemists, Agricultural Chemists, Biochemists, Biophysicists, Environmental Engineers.

IMPACT FACTOR

2012: 2.505 © Thomson Reuters Journal Citation Reports 2013

ABSTRACTING AND INDEXING

Chemical Abstracts
Chemical Engineering Abstracts
Current Contents/Physics, Chemical, & Earth Sciences
Engineered Materials Abstracts
Engineering Index

FIZ Karlsruhe Metals Abstracts Polymer Contents Scopus

EDITORIAL BOARD

Editors-in-Chief

- Y. Tezuka, Tokyo Institute of Technology, Meguro-Ku, Japan, Email: rfp-editor@op.titech.ac.jp Editors
- R. Advincula, Dept. of Macromolecular Science and Engineering, Case Western Reserve University, 2100 Adelbert Road, Kent Hale Smith Bldg., Cleveland, OH 44106, USA, Email: rca41@case.edu A. Bismarck, Dept. of Chemical Engineering, Polymer & Composite Engineering (PaCE) Group, Imperial College London, South Kensington Campus, London, SW7 AZ, UK, Email: a.bismarck@imperial.ac.uk

Editorial Board

- S.D. Alexandratos, City University of New York (CUNY), New York, NY, USA W.C. Chen, National Taiwan University, Taipei, Taiwan, ROC P. Cormack, University of Strathclyde, Glasgow, UK
- V.A. Davankov, Russian Academy of Sciences, MOSCOW, Russian Federation
- F. Du Prez, Universiteit Gent, Gent, Belgium
- W.T. Ford, Oklahoma State University, Stillwater, OK, USA
- J. Frechet, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia
- S.M. Grayson, Tulane University, New Orleans, LA, USA
- W. Hayes, University of Reading, Reading, UK
- P. Hodge, University of Manchester, Manchester, UK
- R. Hoogenboom, Ghent University, Ghent, Belgium
- S. Itsuno, Toyohashi University of Technology, Toyohashi, Japan
- K. Jerabek, Academy of Sciences of the Czech Republic, PRAGUE 6, Czech Republic
- T. Kakuchi, Graduate School of Engineering Management, Shibaur, Tokyo, Japan
- Y. Nagasaki, University of Tsukuba, Tsukuba, Japan
- S. Rimmer, University of Sheffield, Sheffield, UK
- H. Schlaad, Max Planck Institute (MPI) of Colloids and Interfaces, Golm, Germany
- A. Sengupta, Lehigh University, Bethlehem, PA, USA D. Sherrington, University of Strathclyde, Glasgow, UK
- V.S. Soldatov, National Academy of Sciences of Belarus (NASB), Minsk, Belarus N. Tirelli, University of Manchester, Manchester, England, UK
- B. Voit, Leibniz Institute of Polymer Research, Dresden, Germany
- G. Wegner, Max Planck Institute (MPI) for Polymer Research, Mainz, Germany T. Yamamoto, Tokyo Institute of Technology, Midori-ku Yokohama, Japan

GUIDE FOR AUTHORS INTRODUCTION

The Journal publishes papers dealing with new ideas and developments in the science and technology of polymers with functional groups that provide specific chemical reactivity or physico-chemical behaviour.

The scope covers functional polymers, acting as reagents and catalysts, with specific emphasis on solid- or gel-state chemistry; carriers of protecting groups or biofunctional groups; templating agents and functional matrices; ion-exchangers, selective sorbents, chelating agents; supports for enzymes and cells; electro-active and sensing materials. It also

includes advanced polymer synthesis techniques. the study of polymer networks and rheology and processing of functional polymers.

The Journal addresses two main audiences: those engaged in the synthesis of new materials and the development of novel techniques, and those concerned with technology and practical applications in the laboratory or plant. The Journal encourages, and serves as a forum for, the dialogue between these two groups.

Types of Papers

Contributions have to present thorough molecular and material characterisation data, and may deal with the synthesis of the above polymers or with their applications in organic synthesis, catalysis, water or effluent treatment, separations, recovery, lithography, microelectronics, information storage, energy conversion, diagnostics, drug delivery, biotechnology coating and encapsulation, and adhesion.

Papers on a broad spectrum of topics are encouraged. Emphasis is on work at the frontiers of science or technology and furthering the interaction between researcher and practical engineer, rather than on details of theory or application. Full-length papers and review articles will be considered. However, authors intending to write a review should contact an Editor first. Uninvited reviews will not be considered. All material submitted must be original, that is it may not have been submitted elsewhere for publication.

Lack of originality, insufficient molecular characterisation, poor comparison with the current state of literature and with the authors' own production are, individually, sufficient reasons for rejection.

Poor English language is another reason for rejection. Authors are invited to use native speakers for a revision of their manuscripts prior to submission.

BEFORE YOU BEGIN

Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics.

Conflict of interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck http://www.elsevier.com/editors/plagdetect.

Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Copyright

This journal offers authors a choice in publishing their research: Open Access and Subscription. For Subscription articles

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' more information on this and copyright, http://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult http://www.elsevier.com/permissions.

For Open Access articles

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see http://www.elsevier.com/OAauthoragreement). Permitted reuse of open access articles is determined by the author's choice of user license (see http://www.elsevier.com/openaccesslicenses).

Retained author rights

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articlesplease see

http://www.elsevier.com/journal-authors/author-rights-and-responsibilities.

Open access articles please see http://www.elsevier.com/OAauthoragreement.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report;

and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. Please see http://www.elsevier.com/funding.

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

Open access

This journal offers authors a choice in publishing their research:

Open Access

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An Open Access publication fee is payable by authors or their research funder Subscription
- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)
- No Open Access publication fee

All articles published Open Access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non¬commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non¬commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published Open Access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The publication fee for this journal is \$2500, excluding taxes. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.

Language and language services

Manuscripts should be written in English (American or British usage is accepted, but not a mixture of these) in a clear and concise manner and follow the style of a current issue of Reactive and Functional Polymers. Authors whose native language is not English should have

the spelling, grammar, and style checked by someone fully proficient in the English language. Manuscripts which are not written in fluent English will be rejected automatically without refereeing.

Authors in Japan kindly note that, upon request, Elsevier Japan will provide a list of people who can check and improve the English of an article before submission. Contact our Tokyo office: Elsevier Japan K.K., 1-9-15 Higashi Azabu, Minato-ku, Tokyo 106-0044, Japan Tel.: +81-3-5561-5032; fax: +81-3-5561-5045; e-mail: jp.info@elsevier.com

Authors who require further information about language editing and copyediting services preand post-submission please visit http://www.elsevier.com/languageediting or our customer support site at http://support.elsevier.com for more information. Please note that Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services or in any advertising. For more information please refer to our Terms and Conditions http://www.elsevier.com/termsandconditions.

Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

Submit your article

Please submit your article via http://ees.elsevier.com/react.

PREPARATION

Article structure

Format

Manuscripts must be written with 1 1/2 line spacing, using a 12 pt Arial or Times font. All pages must be numbered consecutively. Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to "the text". Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Title page: essential information

- Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.
- Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.
- Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually

did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract, of not more than 200 words, is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Keywords

Immediately after the abstract, provide 5 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Introduction

Statement of the problem. Outline of the paper and important findings. Provide an appropriate literature review and a statement of novelty of the approach relative to the state of the art, or a clear justification of the study.

Experimental

Please divide into the following sections: Materials and Physico-chemical characterization to provide, respectively, the details of all the materials employed and of all instrumental techniques used. Sections for the Synthesis, Physical characterization, Physico-chemical characterization or Biological experiments will contain experimental details. If you feel that equations need to be provided in support of the experimental description (e.g. to show how a yield, a swelling degree, a diffusion coefficient were calculated, to illustrate a mathematical model, etc.), add also a Theory section.

List of Symbols: Please include a list in the experimental section if more than about 10 symbols are used. Define all symbols and include units.

Results and discussion

Report the results in a clear and concise fashion, and explore their significance Avoid extensive citations and discussion of published literature. Please move any detailed description of equations or methods to the experimental section (Theory).

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

References

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: " as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result"

List: Number the references (numbers in square brackets) in the list in the order in which they appear

in the text.

Examples:

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun. 163 (2000) 51-59.

Reference to a book:

- [2] W. Strunk Jr., E.B. White, The Elements of Style, third ed., Macmillan, New York, 1979. Reference to a chapter in an edited book:
- [3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 1999, pp. 281-304.

Figure captions

Ensure that each illustration has a caption. Supply captions in a separate list after the references section, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Schemes and figures

All the display elements should be placed in a separate section after the figure captions. Graphs and pictures should be numbered as figures. Schemes should contain reaction or process graphical descriptions and must be numbered separately from the other display elements. The place of schemes and figures should be clearly indicated in the text and their captions should be provided after the references section (see above). Generally graphs should be in black and white, otherwise you will incur in charges for graphs in colour. Please avoid the use of splines in graphs, which suggest the existence of a mathematical model for the data. Graphs should contain data points (with error bars) possibly connected by straight lines (as guide for eyes) or columns. The background of the graphs should be white, no grid used. Finally, the legend should not be embedded in a box. The font for the legend, axis labels and any other additional text should be Arial.

Tables

Number tables consecutively in accordance with their appearance in the text and place them in a separate section at the end of the manuscript. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

IUPAC Guidelines for Polymer Nomenclature

Authors are invited to follow IUPAC recommendations for naming and drawing polymers. A two-page guide is available here: http://www.iupac.org/nc/home/projects/project-db/project-details.html?tx_wfqbe_pi1%5Bproject_nr%5D=2

Math formulae

Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Electronic artwork General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website: http://www.elsevier.com/artworkinstructions

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below): EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi. TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi. TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi. Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions. Please note: Because of technical complications which can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item. Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes) Further considerations
- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at http://support.elsevier.com.

AFTER ACCEPTANCE

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B): http://dx.doi.org/10.1016Zj.physletb.2010.09.059

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Online proof correction

Corresponding authors will receive an e-mail with a link to our ProofCentral system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately - please upload all of your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received. *Offprints*

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail (the PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use). For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints Elsevier's at any time via (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within single (http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/booklets).

AUTHOR INQUIRIES

For inquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage. For detailed instructions on the preparation of electronic artwork, please visit http://www.elsevier.com/artworkinstructions. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at http://www.elsevier.com/trackarticle. You can also check our Author **FAQs** at http://www.elsevier.com/authorFAQ and/or contact Customer Support via http://support.elsevier.com.

© Copyright 2012 Elsevier | http://www.elsevier.com



COMPOSITES SCIENCE AND TECHNOLOGY IF: 4.141

Preparation

Use of wordprocessing software

It is important that the file be saved in the native format of the wordprocessor used. The text shouldbe in single-column format. Keep the layout of the text as simple as possible. Most formatting codeswill be removed and replaced on processing the article. In particular, do not use the wordprocessor'soptions to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for eachindividual table and not a grid for each row. If no grid is used, use tabs, not spaces, to aligncolumns. The electronic text should be prepared in a way very similar to that of conventionalmanuscripts (see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Note that source files of figures, tables and textgraphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'functions of your wordprocessor.

Article structure

Follow this order when typing manuscripts: Title, Authors, Affiliations, Abstract, Keywords, Maintext, Acknowledgements, Appendix, References, Figure Captions and then Tables. Authors should consult a recent issue of the journal for style if possible. The Editors reserve the right to adjust style to certain standards of uniformity.

The use of property names should be avoided as far as possible, but may be acceptable where, in the Editors opinion, the proprietary name is a universally known description of the material in question, eg Kevlar-49. *Text Layout*

Use double spacing and wide (3 cm) margins. (Avoid full justification, i.e., do not use a constantright-hand margin.) Ensure that each new paragraph is clearly indicated. Present tables and figurelegends on separate pages at the end of the manuscript. If possible, consult a recent issue of thejournal to become familiar with layout and conventions. Number all pages consecutively, use 12 ptfont size and standard fonts. *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1(then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may begiven a brief heading. Each heading should appear on its own separate line. *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literaturesurvey or a summary of the results. *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Resultsand Discussion section is often appropriate. Avoid extensive citations and discussion of publishedliterature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which maystand alone or

form a subsection of a Discussion or Results and Discussion section. Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations inappendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequentappendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc. Essential title page information

- *Title*. Concise and informative. Titles are often used in information-retrieval systems. Avoidabbreviations and formulae where possible.
- Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work wasdone) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone and fax numbers (withcountry and area code) are provided in addition to the e-mail address and the complete postaladdress. Contact details must be kept up to date by the corresponding author.
- *Present/permanent address*. If an author has moved since the work described in the article wasdone, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as afootnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of theresearch, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Keywords

Authors should select a maximum of five keywords from the list at the end of these instructions. Each Keyword should be accompanied by the capital letter denoting the category from which thekeyword has been selected. If authors wish they may nominate one keyword which is not included in the list below. The list of up to five keywords should appear on the title page of each papersubmitted for consideration, following the abstract.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their firstmention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article. Abbreviations for units should follow the suggestions of the British Standards publication BS 1991. The full stop should not be included in abbreviations, eg m (not m.), ppm (not p.p.m.): '%' and '/'should be used in preference to 'per cent' and 'per'. Where abbreviations are likely to causeambiguity or not be readily understood by an international readership, units should be given in full.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and donot, therefore, include them on the title page, as a footnote to the title or otherwise. List here those

individuals who provided help during the research (e.g., providing language help, writing assistanceor proof reading the article, etc.).

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). Ifother units are mentioned, please give their equivalent in SI.

Nomenclature and units

Follow internationally accepted rules and conventions: use the international system of units (SI). Ifother quantities are mentioned, give their equivalent in SI. You are urged to consult IUPAC:Nomenclature of Organic Chemistry: http://www.iupac.org/ for further information.

Math formulae

Present simple formulae in the line of normal text where possible and use the solidus (/) instead of ahorizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented initalics. Powers of e are often more conveniently denoted by exp. Number consecutively anyequations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this featuremay be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list. *Table footnotes*

Indicate each footnote in a table with a superscript lowercase letter.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Save text in illustrations as 'graphics' or enclose the font.

- Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Produce images near to the desired size of the printed version.
- Submit each figure as a separate file.

A detailed guide on electronic artwork is available on our

website:http://www.elsevier.com/artworkinstructions

You are urged to visit this site; some excerpts from the detailed information are given here. Formats

Regardless of the application used, when your electronic artwork is finalised, please 'save as' or

convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS: Vector drawings. Embed the font or save the text as 'graphics'.

TIFF: Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi isrequired.

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel)then pleasesupply 'as is'.**Please do not:**

- Supply files that are optimised for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is toolow;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content. *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figuresthen Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web(e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.

Please note: Because of technical complications which can arise by converting color figures to 'grayscale' (for the printed version should you not opt for color in print) please submit in addition usableblack and white versions of all the color illustrations.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. Acaption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviationsused.

Text graphics

Text graphics may be embedded in the text at the appropriate position. If you are working withLaTeX and have such features embedded in the text, these can be left. Further, high-resolutiongraphics files must be provided separately whether or not the graphics are embedded. See further under Electronic artwork.

Tables

Number tables consecutively in accordance with their appearance in the text. Place footnotes totables below the table body and indicate them with superscript lowercase letters. Avoid

verticalrules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicateresults described elsewhere in the article.

References Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and viceversa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication. Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication,

etc.), should also be given. Web references can be listed separately (e.g., after the reference list)under a different heading if desired, or can be included in the reference list.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations inthe text) to other articles in the same Special Issue.

Reference management software

This journal has standard templates available in key reference management packages EndNote(http://www.endnote.com/support/enstyles.asp) and Reference Manager

(http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, authors onlyneed to select the appropriate journal template when preparing their article and the list of referencesand citations to these will be formatted according to the journal style which is described below.

Reference style

All publications cited in the text should be presented in a list of references following the text of themanuscript. In the text refer to references by a number in square brackets on the line (e.g. Since Wu[1]), and the full reference should be given in a numerical list at the end of the paper.

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item. **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone and fax numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description,

footnotes)Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)

- Color figures are clearly marked as being intended for color reproduction on the Web (free ofcharge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied forprinting purposesFor any further information please visit our customer support site at

After acceptance

Use of the Digital Object Identifier

http://support.elsevier.com.

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOIconsists of a unique alpha-numeric character string which is assigned to a document by the the the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yetreceived their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters* B):http://dx.doi.org/10.1016/i.physletb.2010.09.059

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never tochange.

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we donot have an e-mail address then paper proofs will be sent by post) or, a link will be provided in thee-mail so that authors can download the files themselves. Elsevier now provides authors with PDFproofs which can be annotated; for this you will need to download Adobe Reader version 7 (orhigher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF fileswill accompany the proofs (also given online). The exact system requirements are given at theAdobe site: http://www.adobe.com/products/reader/tech-specs.html.

If you do not wish to use the PDF annotations function, you may list the corrections (includingreplies to the Query Form) and return them to Elsevier in an e-mail. Please list your correctionsquoting line number. If, for any reason, this is not possible, then mark the corrections and any othercomments (including replies to the Query Form) on a printout of your proof and return by fax, orscan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to thearticle as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately - pleaselet us have all your corrections within 48 hours. It is important to ensure that all corrections are sentback to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proof reading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Offorints

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. Foran extra charge, paper offprints can be ordered via the offprint order form which is sent once thearticle is accepted for publication. The PDF file is a watermarked version of the published articleand includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

9.2 Trabalhos apresentados em Congressos

 Antithrombin purification by heparin affinity chromatography using magnetic particles coated with polyaniline.

Autores: MERCES, A. A. D.; **SILVA, R. S.**; CARVALHO JUNIOR, L. B. Reunião Regional Nordeste da Sociedade Brasileira de Bioquímica e Biologia Molecular SBBq e 4th International Symposium in Biochemistry of Macromolecules

and Biotechnology, Recife, PE, 2012.

 Imobilização de heparina em partículas ferromagnéticas e seu uso na purificação de proteínas plasmáticas.

Autores: MERCES, A. A. D.; SILVA, R. S.; CARVALHO JUNIOR, L. B.

XI Curso de Inverno Bioquímica e Biologia Molecular. Faculdade de Medicina de Ribeirão Preto FMRP/USP, Ribeirão Preto, SP, 2012.

 Purificação de antitrombina via adsorção por afinidade à heparina imobilizada em dacron ferromagnético. Autores: MERCES, A. A. D.; SILVA, R. S.; CARVALHO JUNIOR, L. B.

VII Reunião Regional da Federação de Sociedades de Biologia Experimental-FeSBE. Maceió, AL, 2012.

Purificação de Proteínas Plasmáticas via Cromatografia de Afinidade à Heparina.

Autores: MERCES, A. A. D.; SILVA, R. S.; CARVALHO JUNIOR, L. B.

XVIII Semana de Biomedicina - Inovação em Saúde e Difusão do Conhecimento Científico, Recife, PE, 2011.

9.3 Premiações

 Antithrombin purification by heparin affinity chromatography using magnetic particles coated with polyaniline.

MELHOR CARTAZ CIENTÍFICO, Prêmio "Marciolino Lins" apresentado na XI Reunião Regional Nordeste da SBBq.

 Imobilização de heparina em partículas ferromagnéticas e seu uso na purificação de proteínas plasmáticas.

TERCEIRO MELHOR trabalho apresentado no XI Curso de Inverno em Bioquímica e Biologia Molecular da FMRP/USP.

 Imobilização de Heparina em partículas Ferromagnéticas e seu uso na Purificação de Proteínas Plasmáticas.

SEGUNDO MELHOR trabalho apresentado no XIX CONIC da UFPE, Recife, PE.

9.4 Orientações e Colaborações

Co-orientação de **Aurenice Arruda das Merces.** Iniciação Científica – Curso de Biomedicina

- Imobilização de Heparina em partículas Ferromagnéticas e seu uso na Purificação de Proteínas Plasmáticas. 2011, Recife, PE.
- Heparinização de Partículas de Magnetita revestidas com Polianilina e seu uso na Separação por afinidade de proteínas plasmáticas. 2012, Recife, PE.
- Imobilização de Heparan Sulfato Em Partículas Ferromagnéticas e seu uso na Separação/Purificação de proteínas plasmáticas. 2013, Recife, PE.